2007
Published by the
National Pharmaceutical Council, Inc.
1894 Preston White Drive
Reston, VA 20191-5433
©2007
by the National Pharmaceutical Council
This compilation of data on State Medical Assistance Programs (Title XIX) presents a general
overview of the characteristics of State programs, together with detailed information on the
pharmaceutical benefits provided. The data collection effort covers all States with Medicaid programs
and the District of Columbia.
Information for this compilation was acquired from multiple sources, including a survey of Medicaid
prescription drug programs administered for the National Pharmaceutical Council by United
BioSource Corporation with assistance from Total Compensation Solutions. Additional assistance
was provided by StateScape and Hmetrix. While we have checked all secondary data in the book for
consistency relative to the original source, we have not validated the original data reported by the
Centers for Medicare and Medicaid Services (CMS) and other organizations.
The data in this compilation were compiled under the direction of David Goldenberg, Ph.D., with
assistance from Errica Philpott, Steven Heath, Stanley Weintraub, Edward Steinhouse, J.D., Elizabeth
Segall, Vishal Gupta, and Michael Sanky of United BioSource Corporation. Paul Gavejian, Michael
Steele, and Matthew Leach of Total Compensation Solutions prepared and conducted the 2007 survey.
George Chalissery and Hmetrix were responsible for aggregating the data on number of prescriptions
and drug expenditures by therapeutic category. David Schulz at StateScape provided updated
information on State officials, State professional societies, and State pharmaceutical assistance
programs. As always, Gary Persinger and Kimberly Westrich of the National Pharmaceutical Council
provided valuable input and support.
National Pharmaceutical Council Pharmaceutical Benefits 2007
TABLE OF CONTENTS
i
National Pharmaceutical Council Pharmaceutical Benefits 2007
APPENDIXES
Appendix A: State and Federal Medicaid Contacts .................................................................... A-1
Appendix B: Medicaid Program Statistics – CMS MSIS Tables ................................................B-1
Appendix C: Medicaid Rebate Law.............................................................................................C-1
Appendix D: Federal Upper Limits for Multiple Source Products ............................................. D-1
Appendix E: Glossary .................................................................................................................. E-1
ii
National Pharmaceutical Council Pharmaceutical Benefits 2007
Section 1:
Introduction
1-1
National Pharmaceutical Council Pharmaceutical Benefits 2007
1-2
National Pharmaceutical Council Pharmaceutical Benefits 2007
INTRODUCTION
The 2007 edition of Pharmaceutical Benefits Under State Medical Assistance Programs marks the 41st
year that the National Pharmaceutical Council (NPC) has compiled and published one of the largest
sources of information on pharmacy programs within the State Medical Assistance Programs (Title
XIX) and expanded pharmacy programs for the elderly and disabled. Due to the hard work of a skilled
team and countless contributors, the “Medicaid Compilation” has become a standard reference and
invaluable resource in government offices, research libraries, consultancies, the pharmaceutical
industry, numerous businesses, and policy organizations.
The data used to create each edition of the Compilation are assembled from numerous sources. The
Compilation incorporates information on each State pharmacy program from an annual NPC survey of
State Medicaid program administrators and pharmacy consultants, statistics from the Centers for
Medicare and Medicaid Services (CMS), and information from other Federal agencies and
organizations.
In order to give a better understanding of the content of the “Medicaid Compilation,” the information
contained in this version of the book is summarized below by section:
! Section 2: Contains an overview of the Medicaid program (which is current at press time and
has not been revised to reflect any future changes that may result from the Deficit Reduction
Act), details about Medicaid managed care enrollment, including a breakdown by plan type
and enrollment by plan type, and a synopsis of 1915(b) waivers and 1115 demonstrations.
! Section 4: Provides Medicaid pharmacy program characteristics, drawn largely from the 2007
NPC annual survey of State pharmacy program administrators. In addition, this section
provides Medicaid eligibility statistics from CMS for fiscal year 2004 and program
expenditure data for fiscal year 2005. Medicaid pharmacy programs are characterized by
estimates of total expenditures, drug payments, drug benefit design, and pharmacy payment
and patient cost sharing.
! Section 5: Contains detailed profiles of the States’ Medicaid pharmacy programs. This
section contains a description of medical assistance benefits and eligibles, drug payments and
recipients, benefit design, pharmacy payment and patient cost sharing, use of managed care,
and State contacts.
1-3
National Pharmaceutical Council Pharmaceutical Benefits 2007
As we continue to update and discover data, we are able to improve the Compilation with new tables
and sources that we believe enhance its overall significance to the user. These new tables and sources
include:
NPC gratefully acknowledges the cooperation and assistance of the many State and Federal program
officials and their staffs. With their cooperation, we were able to achieve a 90 percent response rate to
the 2007 Survey. Unfortunately, not all States were able to submit revised/updated information. In
such instances, we have incorporated the most recently available data from other sources. However,
for these States, much of the information may reflect data that have been presented in previous
versions of the Compilation.
We would also like to thank United BioSource Corporation and their subcontractors, Total
Compensation Solutions, Hmetrix, and StateScape, for administering the survey and compiling
important parts of the information on State pharmacy programs. We hope you continue to find the
information contained in this compilation useful and, as always, we welcome your suggestions and
comments.
Gary Persinger
Vice President, Health Care Systems
National Pharmaceutical Council
1-4
National Pharmaceutical Council Pharmaceutical Benefits 2007
Section 2:
The Medicaid Program
2-1
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-2
National Pharmaceutical Council Pharmaceutical Benefits 2007
MEDICAID ELIGIBILITY
Medicaid Eligibility: Medicaid is a “means tested program for low-income individuals.” To qualify,
a Medicaid recipient must not have “income” or “resources” that exceed the applicable limits
prescribed in the law and regulations.
Every State, in order to receive Federal funding under Title XIX, must provide Medicaid benefits to
certain “categorically needy” persons. These are the “mandatory” categorically needy. In addition,
the State has the option of providing Medicaid benefits to certain additional categories of persons.
These are the “optional” categorically needy. An additional category of Medicaid recipients that a
State may choose to include in its program is the “medically needy.”
Mandatory Categorically Needy: There are numerous and detailed categories under which the
“categorically needy” may qualify for Medicaid benefits. The principal categories of the mandatory
categorically needy are:
! Low-income families with children;
! Recipients of Supplemental Security Income (SSI) for the Aged, Blind, and Disabled
(this includes disabled children);
! Individuals qualified for adoption assistance agreements or foster care maintenance
payments under Title IV-E of the Social Security Act;
! Qualified pregnant women;
! Newborn children of Medicaid-eligible women;
! Various categories of low-income children; and
! Certain low-income Medicare beneficiaries.
Optional Categorically Needy: These are groups of individuals who meet the characteristics of the
mandatory groups, but the eligibility criteria are somewhat more liberally defined. For example, in
determining their incomes and resources, they are allowed to exclude certain kinds of income. The
“optional categorically needy” include individuals who are aged, blind, disabled, caretaker relatives,
and pregnant women who meet the SSI income and resources requirements but are not receiving SSI
cash payments.
Medically Needy: The “medically needy” are those individuals who meet the definitional
requirements described above, except that their income or resources exceed the limitations applicable
to the categorically needy. These individuals can “spend down” to qualify. That is, they can deduct
their medical bills from their income and resources until they meet the applicable income and
resources requirements. Their Medicaid benefits can then begin.
Special Categories: The Medicaid statute also authorizes limited Medicaid benefits to special
categories of individuals. In general, these are individuals whose income and resources would
otherwise be too high to qualify for full Medicaid benefits under the regular provisions.
2-3
National Pharmaceutical Council Pharmaceutical Benefits 2007
For example, a “Qualified Medicare Beneficiary” (QMB) is an individual who qualifies for Medicare
Part A, whose income does not exceed 100 percent of the Federal poverty level, and whose resources
do not exceed twice the SSI resource-eligibility standard. Medicaid coverage of QMBs is limited to
payment of their Medicare cost-sharing charges, such as the Medicare premiums, coinsurance, and
co-payment amounts.
Non-Eligibles: A State can include in its Medicaid program individuals who do not meet the statutory
eligibility criteria. However, the State must pay the full costs for these individuals. There are no
Federal matching payments.
MEDICAID SERVICES
Title XIX lists the many types of medical care that a State may select for inclusion into its Medicaid
State Plan, thus qualifying for Federal matching payments. However, the law requires that certain
basic benefits must be available to all “categorically needy” recipients. These services include:
! Inpatient and outpatient hospital services;
! Physician services;
! Medical and surgical dental services;
! Laboratory and X-ray services;
! Nursing facility services (for persons 21 years of age or older);
! Early and periodic screening, diagnostic, and treatment (EPSDT) services for children
under age 21;
! Family planning services and supplies;
! Home health services for persons eligible for nursing facility services;
! Rural health clinic services and any other ambulatory services offered by a rural health
clinic that are otherwise covered under the State Plan;
! Nurse-midwife services (to the extent authorized under State law);
! Pediatric and family nurse practitioners services; and
! Federally-qualified health center (FQHC) services and any other ambulatory services
offered by an FQHC that are otherwise covered under the State Plan.
If a State chooses to include the “medically needy” population, the State Plan must provide, as a
minimum, the following services:
! Prenatal care and delivery services for pregnant women;
! Ambulatory services to individuals under age 18 and individuals entitled to institutional
services;
! Home health services to individuals entitled to nursing facility services; and
! If the State Plan includes services either in institutions for mental diseases or in
intermediate care facilities for the mentally retarded (ICFs/MR), it must offer medically
needy groups certain specified services provided to the categorically needy.
States may also receive Federal funding if they elect to provide other optional services. The most
commonly covered optional services under the Medicaid program include:
! Clinic services;
! Services of ICFs/MR;
! Nursing facility services (children under 21 years old);
! Prescribed drugs;
! Optometrist services and eyeglasses;
2-4
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-5
National Pharmaceutical Council Pharmaceutical Benefits 2007
furnished by nurses employed by the RHC, and the services are furnished to a homebound recipient
under a written plan of treatment.
2-6
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-7
National Pharmaceutical Council Pharmaceutical Benefits 2007
Voluntary Sterilizations: FFP is available in expenditures for the sterilization of an individual only if
she is at least age 21, has voluntarily given informed consent in accordance with Medicaid
regulations, and is not a mentally incompetent individual.
Physicians’ Services
Physicians’ services are covered, whether provided in the office, the patient’s home, a hospital, a
nursing facility, or elsewhere. Such services must be within the physicians’ scope of practice of
medicine or osteopathy as defined by State law, and by or under the personal supervision of an
individual licensed under State law to practice medicine or osteopathy.
Prescribed Drugs
Prescribed drugs are simple or compound substances or mixtures of substances prescribed for the
cure, mitigation, or prevention of disease, or for health maintenance, which are prescribed by a
physician or other licensed practitioner of the healing arts within the scope of their professional
practice, as defined and limited by Federal and State law (42 CFR 440.120). The drugs must be
dispensed by licensed authorized practitioners on a written prescription that is recorded and
maintained in the pharmacist’s or the practitioner’s records.
Personal support services consist of a variety of services including personal care, targeted case
management, home and community-based care for functionally disabled elderly, rehabilitative
services, hospice services, and nurse-midwife, nurse practitioner, and private duty nursing. Details of
some of these services are provided below:
1. Personal Care Services: Services provided to an individual who is not an inpatient or
resident of a hospital, nursing facility, intermediate care facility for the mentally
2-8
National Pharmaceutical Council Pharmaceutical Benefits 2007
Nurse-Midwife Services
Nurse-midwife services are those concerned with management of the care of mothers and newborns
throughout the maternity cycle. The Omnibus Budget Reconciliation Act of 1980 required that
payment be made providing for nurse-midwife services to categorically needy recipients (42 CFR
440.165). These provisions require States to provide coverage for nurse-midwife services to the
extent that the nurse-midwife is authorized to practice under State law or regulation. The statute also
requires that States offer direct reimbursement to nurse-midwives as one of the payment options.
Nurse-midwives must be registered nurses who are either certified by an organization recognized by
the Secretary of DHHS or who have completed a program of study and clinical experience that has
been approved by the Secretary.
2-9
National Pharmaceutical Council Pharmaceutical Benefits 2007
! The facility receives a grant under sections 329, 330, or 340 of the Public Health Service
Act;
! The Health Resources and Services Administration (HRSA) recommends, and the DHHS
Secretary determines, that the facility meets the requirements of the grant; or
! The Secretary determines that a facility may qualify through waivers of the requirements.
Such a waiver cannot exceed two years.
2-10
National Pharmaceutical Council Pharmaceutical Benefits 2007
Receiving
Total Cash Medically Poverty 1115 MAS
State Eligibles Assistance Needy Related Other Demonstration Unknown
National Total 57,575,692 20,559,445 3,313,195 17,654,820 9,855,899 6,191,305 1,028
Alabama 918,304 274,597 0 473,394 37,592 132,721 0
Alaska 127,779 50,610 0 66,090 11,079 0 0
Arizona 1,394,378 550,709 0 362,701 269,001 211,967 0
Arkansas 700,038 155,522 12,329 300,605 51,721 179,861 0
California 10,619,361 4,724,483 788,296 609,272 2,133,527 2,363,781 2
Colorado 524,760 315,452 0 150,395 58,911 0 2
Connecticut 508,387 82,602 26,014 105,479 294,292 0 0
Delaware 166,604 79,976 0 15,415 43,402 27,811 0
District of Columbia 160,304 86,349 36,611 28,192 9,152 0 0
Florida 2,867,361 1,224,666 106,007 1,080,601 450,243 5,843 1
Georgia 1,759,654 614,889 10,091 833,942 300,732 0 0
Hawaii 223,417 109,093 3,168 51,898 16,745 42,479 34
Idaho 220,535 58,719 0 127,270 34,546 0 0
Illinois 2,264,567 267,908 443,451 1,174,697 134,026 244,485 0
Indiana 982,131 383,104 0 362,910 236,117 0 0
Iowa 399,710 159,714 11,347 130,176 98,473 0 0
Kansas 344,006 131,391 7,356 144,451 60,808 0 0
Kentucky 833,511 389,105 31,828 334,449 78,129 0 0
Louisiana 1,112,345 357,850 13,564 627,371 113,560 0 0
Maine 306,397 58,110 4,171 134,809 79,104 30,203 0
Maryland 845,145 217,098 97,901 350,903 48,168 131,075 0
Massachusetts 1,156,690 314,997 20,511 454,852 135,831 230,499 0
Michigan 1,770,258 466,725 119,909 559,893 524,071 99,621 39
Minnesota 736,476 415,749 26,565 76,547 102,361 115,254 0
Mississippi 785,105 336,988 0 388,839 31,443 27,758 77
Missouri 1,205,751 721,856 0 155,389 198,035 130,471 0
Montana 113,073 48,927 8,897 31,172 24,075 0 2
Nebraska 260,865 67,774 25,254 129,813 37,411 0 613
Nevada 256,841 151,831 0 57,208 47,802 0 0
New Hampshire 134,216 25,945 12,390 66,034 29,847 0 0
New Jersey 988,602 387,466 5,472 381,705 144,339 69,620 0
New Mexico 511,778 199,408 0 199,847 96,967 15,555 1
New York 4,888,941 2,015,032 947,008 677,568 115,119 1,134,214 0
North Carolina 1,526,268 587,054 45,245 779,887 114,082 0 0
North Dakota 74,996 31,543 12,437 13,706 17,310 0 0
Ohio 1,996,065 433,986 0 418,532 1,143,547 0 0
Oklahoma 683,702 184,415 1 444,337 54,949 0 0
Oregon 590,236 178,155 0 168,164 142,621 101,043 253
Pennsylvania 1,890,061 789,183 107,058 637,420 356,400 0 0
Rhode Island 216,052 79,077 4,309 35,939 53,129 43,598 0
South Carolina 990,658 298,965 0 437,149 195,881 58,663 0
South Dakota 124,032 42,396 0 54,045 27,591 0 0
Tennessee 1,619,941 620,026 206,875 294,071 190,654 308,311 4
Texas 3,878,183 853,265 80,981 2,293,200 650,737 0 0
Utah 295,299 98,214 6,292 105,088 62,486 23,219 0
Vermont 163,595 28,197 14,418 50,260 16,350 54,370 0
Virginia 821,256 148,124 10,190 512,062 143,818 7,062 0
Washington 1,195,703 292,146 20,155 382,563 379,282 121,557 0
West Virginia 373,373 121,122 7,504 200,322 44,425 0 0
Wisconsin 971,210 309,474 39,590 145,519 196,363 280,264 0
Wyoming 77,772 19,458 0 38,669 19,645 0 0
1
Eligibles are defined as individuals who were on the Medicaid roles at least one month during the year.
2-11
National Pharmaceutical Council Pharmaceutical Benefits 2007
65 Years and
State Total Eligibles <20 Years 21-64 Years Older Age Unknown
National Total 57,575,692 31,265,163 20,283,550 5,917,484 109,495
Alabama 918,304 486,702 308,866 122,736 0
Alaska 127,779 86,867 33,310 7,602 0
Arizona 1,394,378 715,813 591,870 86,694 1
Arkansas 700,038 420,164 216,520 63,354 0
California 10,619,361 4,952,527 4,764,288 902,525 21
Colorado 524,760 318,605 154,316 51,243 596
Connecticut 508,387 270,566 173,412 64,409 0
Delaware 166,604 82,813 71,492 12,299 0
District of Columbia 160,304 86,818 59,313 14,172 1
Florida 2,867,361 1,644,182 849,036 373,858 285
Georgia 1,759,654 1,114,125 477,959 167,568 2
Hawaii 223,417 110,593 90,064 22,760 0
Idaho 220,535 153,818 53,317 13,400 0
Illinois 2,264,567 1,264,313 627,877 372,369 8
Indiana 982,131 615,708 286,060 80,363 0
Iowa 399,710 228,781 129,581 41,347 1
Kansas 344,006 213,480 97,034 33,492 0
Kentucky 833,511 458,162 282,237 93,085 27
Louisiana 1,112,345 745,594 257,619 109,132 0
Maine 306,397 127,609 144,358 34,428 2
Maryland 845,145 491,203 273,958 79,966 18
Massachusetts 1,156,690 515,616 500,166 140,908 0
Michigan 1,770,258 1,015,405 621,511 133,155 187
Minnesota 736,476 398,610 247,866 89,998 2
Mississippi 785,105 464,734 224,639 95,732 0
Missouri 1,205,751 685,309 419,250 101,188 4
Montana 113,073 65,145 37,477 10,449 2
Nebraska 260,865 164,407 66,519 23,798 6,141
Nevada 256,841 153,307 79,591 23,840 103
New Hampshire 134,216 83,667 36,429 14,115 5
New Jersey 988,602 550,025 295,518 143,059 0
New Mexico 511,778 327,093 151,993 32,692 0
New York 4,888,941 2,112,705 2,174,386 499,842 102,008
North Carolina 1,526,268 860,015 486,217 180,034 2
North Dakota 74,996 39,981 25,360 9,655 0
Ohio 1,996,065 1,139,998 696,688 159,379 0
Oklahoma 683,702 461,685 156,642 65,375 0
Oregon 590,236 289,485 250,518 50,226 7
Pennsylvania 1,890,061 1,013,149 655,551 221,360 1
Rhode Island 216,052 108,448 82,724 24,880 0
South Carolina 990,658 543,494 305,375 141,789 0
South Dakota 124,032 81,288 30,439 12,305 0
Tennessee 1,619,941 747,263 696,060 176,618 0
Texas 3,878,183 2,672,469 801,061 404,632 21
Utah 295,299 175,777 105,137 14,382 3
Vermont 163,595 73,901 68,340 21,354 0
Virginia 821,256 496,821 222,230 102,188 17
Washington 1,195,703 712,093 399,316 84,293 1
West Virginia 373,373 200,481 138,974 33,918 0
Wisconsin 971,210 472,173 344,956 154,054 27
Wyoming 77,772 52,176 20,130 5,464 2
1
Eligibles are defined as individuals who were on the Medicaid roles at least one month during the year.
2-12
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-13
National Pharmaceutical Council Pharmaceutical Benefits 2007
American
Indian/
Total Black/African Alaska Hispanic or
State Eligibles White American Native Asian Latino Other
National Total 57,575,692 24,963,746 13,320,983 833,800 1,502,416 12,533,000 4,421,747
Alabama 918,304 428,801 436,679 2,577 4,240 20,835 25,172
Alaska 127,779 54,040 6,635 47,359 6,523 4,699 8,523
Arizona 1,394,378 485,844 80,073 153,888 17,422 623,427 33,724
Arkansas 700,038 438,290 209,923 5,599 6,669 33,852 5,705
California 10,619,361 2,249,008 976,625 45,748 515,864 5,787,987 1,044,129
Colorado 524,760 243,850 41,584 4,881 6,779 197,336 30,330
Connecticut 508,387 236,498 110,945 986 11,860 147,891 207
Delaware 166,604 72,159 70,292 344 2,521 21,285 3
District of Columbia 160,304 2,697 139,053 47 1,375 12,765 4,367
Florida 2,867,361 1,054,831 844,911 2,904 23,431 714,828 226,456
Georgia 1,759,654 749,052 855,834 1,492 22,350 26,314 104,612
Hawaii 223,417 52,040 3,555 662 68,483 8,157 90,520
Idaho 220,535 196,567 2,086 5,521 1,181 14,841 339
Illinois 2,264,567 963,463 810,940 4,355 54,523 402,105 29,181
Indiana 982,131 669,291 218,553 620 4,009 79,022 10,636
Iowa 399,710 263,799 28,786 1,874 3,559 14,385 87,307
Kansas 344,006 219,138 54,265 4,665 4,454 34 61,450
Kentucky 833,511 672,499 103,601 432 2,920 17,859 36,200
Louisiana 1,112,345 407,018 619,087 2,915 6,173 8,984 68,168
Maine 306,397 291,537 7,123 3,924 2,761 1,052 0
Maryland 845,145 279,384 442,491 1,575 24,435 65,393 31,867
Massachusetts 1,156,690 590,847 126,942 2,895 38,633 188,707 208,666
Michigan 1,770,258 1,016,738 601,030 9,332 26,120 97,695 19,343
Minnesota 736,476 441,501 118,215 28,246 46,631 702 101,181
Mississippi 785,105 263,644 436,995 2,961 3,972 6,636 70,897
Missouri 1,205,751 849,802 298,472 4,006 8,483 62 44,926
Montana 113,073 81,551 1,005 26,408 472 3,629 8
Nebraska 260,865 172,392 33,260 9,073 2,825 97 43,218
Nevada 256,841 120,628 48,411 3,722 8,269 57,862 17,949
New Hampshire 134,216 121,971 2,678 160 1,048 4,691 3,668
New Jersey 988,602 371,025 307,191 3,700 20,609 175,870 110,207
New Mexico 511,778 126,902 10,899 96,357 2,889 264,030 10,701
New York 4,888,941 1,753,381 1,154,965 82,849 286,679 663,942 947,125
North Carolina 1,526,268 668,841 609,834 25,149 14,506 77,777 130,161
North Dakota 74,996 52,578 1,419 16,389 270 0 4,340
Ohio 1,996,065 1,329,951 589,261 2,113 13,587 60,185 968
Oklahoma 683,702 422,119 107,827 87,102 6,837 0 59,817
Oregon 590,236 415,236 25,900 14,440 17,272 109,713 7,675
Pennsylvania 1,890,061 1,126,287 500,438 2,364 36,286 138,164 86,522
Rhode Island 216,052 89,736 18,433 415 5,073 39,218 63,177
South Carolina 990,658 405,429 483,878 1,589 3,126 25,604 71,032
South Dakota 124,032 75,349 2,994 41,959 714 2,660 356
Tennessee 1,619,941 1,060,363 450,537 2,623 3,938 41,376 61,104
Texas 3,878,183 1,012,711 709,856 14,497 56,696 2,045,169 39,254
Utah 295,299 214,958 5,969 10,629 8,844 52,331 2,568
Vermont 163,595 93,595 1,300 245 406 303 67,746
Virginia 821,256 368,434 366,039 1,349 21,394 59,191 4,849
Washington 1,195,703 728,888 71,648 30,407 49,394 162,553 152,813
West Virginia 373,373 352,864 19,798 132 541 30 8
Wisconsin 971,210 544,950 151,348 14,461 25,093 50,166 185,192
Wyoming 77,772 61,269 1,400 5,860 277 1,586 7,380
1
Eligibles are defined as individuals who were on the Medicaid roles at least one month during the year.
2-14
National Pharmaceutical Council Pharmaceutical Benefits 2007
1
Eligibles are defined as individuals who were on the Medicaid rolls at least one month during the year.
2-15
National Pharmaceutical Council Pharmaceutical Benefits 2007
Source: U.S. Department of Commerce, Bureau of the Census, 2004; CMS, MSIS Report, FY 2004.
2-16
National Pharmaceutical Council Pharmaceutical Benefits 2007
Total Net U.S. Medical Assistance Expenditures
by Type of Service, FY 2004 & FY 2005
‡ Values may not add to 100% due to rounding. American Samoa, Guam, N. Mariana Islands, Puerto Rico, and Virgin Islands
excluded.
* Clinic includes clinics, FQHCs, and rural health clinics.
** Other includes hospice, other care services, payments to managed care organizations, etc.
2-17
National Pharmaceutical Council Pharmaceutical Benefits 2007
* The “Enhanced Federal Medical Assistance Percentages” are for use in State Children’s Health Insurance Program under Title XXI, and for some or all
of children’s medical assistance under Medicaid sections 1905(u)(2) and 1905(u)(3).
** The values for the District of Columbia in the table were set for the state plan under titles XIX and XXI and for capitation payments and DSH
allotments under those titles. For other purposes, including programs remaining in Title IV of the Act the Percentage for the District of Columbia is
50.00%.
Source: Federal Register, May 15, 2006, Vol. 71, No. 93, pages 28041-28042, and November 30, 2006, Vol. 71, No. 230, pages 69209-69211.
2-18
National Pharmaceutical Council Pharmaceutical Benefits 2007
Medicaid Total Net Expenditures and Eligibles, 2004
1
Eligibles are defined as individuals who were on the Medicaid roles at least one month during the year.
2-19
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-20
National Pharmaceutical Council Pharmaceutical Benefits 2007
*The data displayed in this table were compiled from the CMS website at
http://www.cms.hhs.gov/NationalSCHIPPolicy/downloads/FY2005AnnualEnrollmentReport.pdf.
Column and row values do not always sum to totals.
** California reported aggregate enrollment for unborn children via email.
NR- State has not reported data via the Statistical Enrollment Data System (SEDS).
Source: CMS, SCHIP Annual Enrollment Report 2005.
2-21
National Pharmaceutical Council Pharmaceutical Benefits 2007
*The data displayed in this table were compiled from the CMS website at http://www.cms.hhs.gov/NationalSCHIPPolicy/
SCHIPER/list.asp.
Column and row values do not always sum to totals.
Source: CMS, SCHIP Annual Enrollment Report 2006 (Revised March 2007).
2-22
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-23
National Pharmaceutical Council Pharmaceutical Benefits 2007
Not a QMB/
State All Eligibles Dual Eligible QMB Only Medicaid SLMB Only
National Total 57,575,692 49,361,011 523,829 4,530,864 422,973
Alabama 918,304 728,680 47,835 85,461 24,539
Alaska 127,779 116,512 3 8,170 148
Arizona 1,394,378 1,269,306 1,218 65,203 11,268
Arkansas 700,038 596,512 23,518 73,501 1,880
California 10,619,361 9,541,090 8,175 954,783 5,224
Colorado 524,760 450,709 8,157 9,125 4,142
Connecticut 508,387 413,315 7,523 44,610 4,071
Delaware 166,604 146,445 4,953 6,404 4,241
District of Columbia 160,304 140,933 69 13,361 962
Florida 2,867,361 2,347,199 34,756 333,640 44,766
Georgia 1,759,654 1,505,647 58,508 14,974 27,953
Hawaii 223,417 194,383 83 24,032 1,874
Idaho 220,535 197,631 3,363 11,105 0
Illinois 2,264,567 1,918,663 10,696 145,179 2,724
Indiana 982,131 845,259 9,807 73,969 7,190
Iowa 399,710 326,949 4,723 31,242 3,573
Kansas 344,006 286,012 5,343 29,169 3,303
Kentucky 833,511 676,706 30,554 85,767 11,446
Louisiana 1,112,345 948,819 30,737 106,564 16,851
Maine 306,397 246,169 1,205 28,966 5,509
Maryland 845,145 710,870 16,373 47,416 6,330
Massachusetts 1,156,690 928,406 194 92,740 16,809
Michigan 1,770,258 1,563,692 1,516 52,670 7,120
Minnesota 736,476 616,061 2,289 63,342 5,460
Mississippi 785,105 634,520 1,267 42,979 2,079
Missouri 1,205,751 1,033,623 5,183 71,830 3,841
Montana 113,073 94,901 536 11,057 0
Nebraska 260,865 221,958 0 23,823 2,296
Nevada 256,841 219,552 9,532 19,578 4,648
New Hampshire 134,216 111,012 2,118 5,773 1,353
New Jersey 988,602 805,847 0 138,578 20,062
New Mexico 511,778 465,072 12,660 29,225 0
New York 4,888,941 4,249,119 2,690 330,088 1,231
North Carolina 1,526,268 1,234,899 602 201,784 29,149
North Dakota 74,996 60,174 1,176 1,216 818
Ohio 1,996,065 1,739,767 26,484 123,336 13,209
Oklahoma 683,702 586,738 0 81,155 9,734
Oregon 590,236 510,214 11,052 32,249 6,462
Pennsylvania 1,890,061 1,551,971 692 218,444 24,471
Rhode Island 216,052 177,531 609 18,815 2,223
South Carolina 990,658 856,853 0 76,944 6,238
South Dakota 124,032 105,696 2,958 9,724 1,506
Tennessee 1,619,941 1,311,747 13,332 132,679 11,220
Texas 3,878,183 3,391,054 71,506 275,155 36,114
Utah 295,299 270,361 317 14,353 927
Vermont 163,595 133,320 189 10,003 497
Virginia 821,256 666,656 20,455 91,721 14,559
Washington 1,195,703 1,068,860 10,380 87,970 7,598
West Virginia 373,373 312,397 12,948 0 0
Wisconsin 971,210 762,708 3,938 78,127 4,595
Wyoming 77,772 68,493 1,607 2,865 760
1
Eligibles are defined as individuals who were on the Medicaid roles at least one month during the year.
QMB Only = Qualified Medicare Beneficiaries Without Other Medicaid
QMB/ Medicaid = QMBs With Full Medicaid
SLMB Only = Specified Low-Income Beneficiaries Without Other Medicaid
2-24
National Pharmaceutical Council Pharmaceutical Benefits 2007
SLMB/
State Medicaid QDWI QI(1) QI(2) Other
National Total 225,355 78 218,908 570 2,292,104
Alabama 4,074 0 14,239 2 13,474
Alaska 0 0 0 0 2,946
Arizona 0 0 9,439 0 37,944
Arkansas 0 31 4,593 3 0
California 0 5 3,376 0 106,708
Colorado 5 0 1,789 1 50,832
Connecticut 6,249 0 6,993 0 25,626
Delaware 0 0 1 0 4,560
District of Columbia 744 0 376 7 3,852
Florida 20,765 0 27,691 0 58,544
Georgia 2,623 3 13,774 0 136,172
Hawaii 0 0 0 0 3,045
Idaho 0 0 0 0 8,436
Illinois 22,529 0 13,474 0 151,302
Indiana 13,577 2 4,115 0 28,212
Iowa 7,600 0 1,766 0 23,857
Kansas 1,528 0 1,314 0 17,337
Kentucky 4,322 1 5,038 0 19,677
Louisiana 100 1 9,245 14 14
Maine 1,792 2 2,788 484 19,482
Maryland 0 0 2,430 0 61,726
Massachusetts 0 0 0 0 118,541
Michigan 8,216 3 3,073 10 133,958
Minnesota 11,291 0 2,465 0 35,568
Mississippi 14,612 1 801 0 88,846
Missouri 11,258 0 266 0 79,750
Montana 0 0 0 0 6,579
Nebraska 0 1 0 0 12,787
Nevada 1,398 0 2,098 3 32
New Hampshire 902 3 565 0 12,490
New Jersey 0 0 8,660 0 15,455
New Mexico 0 0 0 0 4,821
New York 5,550 0 1,657 1 298,605
North Carolina 6,134 0 13,199 0 40,501
North Dakota 190 0 322 0 11,100
Ohio 38 0 6,101 0 87,130
Oklahoma 1,246 0 4,788 41 0
Oregon 5,377 0 3,303 0 21,579
Pennsylvania 16,962 0 14,169 0 63,352
Rhode Island 0 0 1,459 0 15,415
South Carolina 0 1 3,980 2 46,640
South Dakota 1,044 0 655 2 2,447
Tennessee 24,412 0 0 0 126,551
Texas 14,966 0 18,387 0 71,001
Utah 1,551 0 496 0 7,294
Vermont 854 0 0 0 18,732
Virginia 0 24 5,359 0 22,482
Washington 1,852 0 3,557 0 15,486
West Virginia 0 0 0 0 48,028
Wisconsin 7,911 0 747 0 113,184
Wyoming 3,683 0 360 0 4
1
Eligibles are defined as individuals who were on the Medicaid roles at least one month during the year.
SLMB/Medicaid = SLMBs with full Medicaid
QDWI = Qualified Disabled and Working Individuals
QI 1 = Qualifying Individuals (1)
QI 2 = Qualifying Individuals (2)
Other = Other Dual Eligibles, Dual Category Unknown, and Dual Status Unknown
2-25
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-26
National Pharmaceutical Council Pharmaceutical Benefits 2007
SLMB/
State Medicaid QDWI QI (1) QI (2) Other
National Total $4,307,421,421 $243,359 $217,035,370 $153,285 $51,496,172,532
Alabama $122,139,141 $0 $5,661,187 $79,664 $1,177,706,961
Alaska $0 $0 $0 $0 $91,509,709
Arizona $0 $0 $0 $0 $442,086,581
Arkansas $0 $219,793 $946,387 $0 $33,142,588
California $0 $68 $1,963,877 $0 $3,361,887,172
Colorado $5,963 $0 $203,923 $0 $964,395,146
Connecticut $225,520,619 $0 $540,863 $0 $726,835,981
Delaware $0 $0 $0 $0 $173,925,142
District of Columbia $10,852,595 $0 $980,889 $0 $199,449,189
Florida $451,995,102 $0 $49,787,717 $0 $2,397,388,527
Georgia $58,121,538 $0 $4,848,443 $0 $2,096,626,019
Hawaii $0 $0 $0 $0 $112,053,530
Idaho $0 $0 $0 $0 $198,840,638
Illinois $363,664,994 $0 $86,368,096 $0 $3,061,263,087
Indiana $220,274,012 $0 $832,418 $0 $593,204,636
Iowa $141,284,567 $0 $535,775 $0 $358,436,734
Kansas $16,654,868 $0 $264,421 $0 $418,769,315
Kentucky $111,728,632 $6 $871,349 $0 $342,239,202
Louisiana $1,475,519 $0 $784,091 $0 $112,268,665
Maine $38,238,724 $1,006 $1,324,604 $2,035 $397,845,244
Maryland $0 $0 $1,801,891 $0 $822,708,595
Massachusetts $0 $0 $0 $0 $2,302,377,448
Michigan $167,773,217 $12,517 $4,973,315 $65,437 $2,581,194,333
Minnesota $223,013,200 $0 $806,762 $0 $672,103,614
Mississippi $61,632,145 $887 $528,046 $0 $1,473,492,753
Missouri $144,113,748 $0 $185,166 $0 $1,075,905,374
Montana $0 $0 $0 $0 $125,372,665
Nebraska $0 $0 $0 $0 $543,293,513
Nevada $29,887,741 $0 $492,586 $0 $17,136,393
New Hampshire $16,311,953 $0 $87,587 $0 $306,442,738
New Jersey $0 $0 $1,488,796 $0 $362,686,107
New Mexico $0 $0 $0 $0 $338,795,751
New York $174,249,724 $0 $27,250,325 $3,820 $9,755,123,550
North Carolina $168,238,567 $0 $4,773,427 $0 $615,739,158
North Dakota $2,401,884 $0 $28,722 $0 $274,455,893
Ohio $308,828 $0 $8,773,647 $0 $2,472,284,828
Oklahoma $17,184,163 $0 $590,267 $2,209 $13,890,630
Oregon $93,177,180 $0 $423,435 $0 $330,432,672
Pennsylvania $474,498,156 $0 $3,469,894 $0 $1,804,511,437
Rhode Island $0 $0 $289,060 $0 $493,946,620
South Carolina $0 $292 $798,598 $0 $1,334,593,571
South Dakota $26,692,103 $0 $133,490 $120 $56,692,663
Tennessee $233,115,834 $0 $0 $0 $1,061,786,754
Texas $374,700,130 $0 $1,280,943 $0 $1,325,057,338
Utah $31,409,379 $0 $229,963 $0 $441,793,457
Vermont $5,002,198 $0 $0 $0 $200,494,040
Virginia $0 $8,790 $1,618,639 $0 $501,685,147
Washington $12,335,080 $0 $847,399 $0 $910,563,731
West Virginia $0 $0 $0 $0 $1,028,273,593
Wisconsin $177,580,212 $0 $206,046 $0 $991,562,091
Wyoming $111,839,705 $0 $43,326 $0 $1,902,009
1
Eligibles are defined as individuals who were on the Medicaid roles at least one month during the year.
SLMB/Medicaid = SLMBs with full Medicaid
QDWI = Qualified Disabled and Working Individuals
QI 1 = Qualifying Individuals (1)
QI 2 = Qualifying Individuals (2)
Other = Other Dual Eligibles, Dual Category Unknown, and Dual Status Unknown
2-27
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-28
National Pharmaceutical Council Pharmaceutical Benefits 2007
Since 1981, when Congress authorized States to implement Section 1915(b) and Section 1115
Medicaid waivers to increase access to managed care and test innovative health care financing and
delivery options, enrollment in Medicaid managed care has grown considerably, although the trend
appears to be leveling off. Since 1993, managed care enrollment has increased from 14.4% to over
65% of total Medicaid enrollment. In 2006, 65.3% of all Medicaid beneficiaries were enrolled in
some type of managed care program. As of June 30, 2006, all but two States (Alaska and Wyoming)
were enrolling Medicaid beneficiaries in some type of managed care plan.
Medicaid managed care beneficiaries can be enrolled in one of five basic Medicaid managed care
plans:
! Health Insuring Organization (HIO): an entity that provides for or arranges for the
provision of care and contracts on a prepaid capitated risk basis to provide a
comprehensive set of services.
! Commercial Managed Care Organization (Com-MCO): a Com-MCO is a health
maintenance organization with a contract under §1876 or a Medicare+Choice
organization, a provider sponsored organization or any other private or public
organization, which meets the requirements of §1902(w). They provide
comprehensive services to commercial and/or Medicare enrollees, as well as
Medicaid enrollees.
! Medicaid-only Managed Care Organization (Mcaid-MCO): an MCO that
provides comprehensive services to Medicaid beneficiaries, but not commercial or
Medicare enrollees.
! Prepaid Inpatient Health Plan (PIHP): an entity that provides less than
comprehensive services on an at-risk basis or one that provides any benefit package
on a non-risk or other than State reimbursement Plan basis; and provides, arranges
for or otherwise has responsibility for the provision of any inpatient hospital or
institutional services.
! Prepaid Ambulatory Health Plan (PAHP): a prepaid ambulatory health plan that
provides less than comprehensive services on an at-risk or other than State Plan
reimbursement basis, and does not provide, arranges for, or otherwise has
responsibility for the provision of any inpatient hospital or institutional services.
! Primary Care Case Management (PCCM): a provider (usually a physician,
physician group practice, or an entity employing or having other arrangements with
such physicians, but sometimes also including nurse practitioners, nurse-midwives,
or physician assistants) who contracts to locate, coordinate, and monitor covered
2-29
National Pharmaceutical Council Pharmaceutical Benefits 2007
primary care (and sometimes additional services). This category includes those
PIHPs that act as PCCMs.
! Program for All-Inclusive Care for the Elderly (PACE): a program that provides
prepaid, capitated comprehensive health care services to the frail elderly.
! “Other” Managed Care Arrangement: An entity where the plan is not considered
a PCCM, PIHP, PAHP, Comprehensive MCO, Medicaid-only MCO, HIO, or PACE.
The most utilized of these plans are Comprehensive MCOs and Prepaid Health Plans.
Source: Medicaid Managed Care Enrollment Report: Summary Statistics as of June 30, 2006. DHHS, CMS, Center for Medicaid
& State Operations.
The following tables provide an overview of Medicaid managed care enrollment at the State level.
2-30
National Pharmaceutical Council Pharmaceutical Benefits 2007
Rank Based on
Medicaid Medicaid Managed Percent in Percent in
State Enrollment Care Enrollment Managed Care Managed Care
National Total 45,652,642 29,830,406 65.34%
Alabama 785,949 497,539 63.30% 38
Alaska 100,720 0 0.00% 51
Arizona 977,094 875,492 89.60% 9
Arkansas 635,065 527,233 83.02% 16
California 6,508,528 3,276,440 50.34% 44
Colorado 391,227 372,046 95.10% 6
Connecticut 395,624 299,052 75.59% 22
Delaware 144,619 110,601 76.48% 21
District of Columbia 137,517 93,182 67.76% 29
Florida 2,276,597 1,491,020 65.49% 33
Georgia 1,321,564 1,290,814 97.67% 4
Hawaii 203,345 162,650 79.99% 20
Idaho 171,795 139,875 81.42% 18
Illinois 1,929,200 140,100 7.26% 50
Indiana 839,101 604,891 72.09% 24
Iowa 329,637 285,163 86.51% 12
Kansas 283,383 161,600 57.03% 42
Kentucky 706,903 652,935 92.37% 7
Louisiana 969,193 689,609 71.15% 25
Maine 243,487 162,397 66.70% 31
Maryland 700,431 489,988 69.96% 26
Massachusetts 1,037,978 627,241 60.43% 41
Michigan 1,523,390 1,292,524 84.85% 15
Minnesota 583,564 371,429 63.65% 37
Mississippi 570,178 58,189 10.21% 49
Missouri 830,262 826,394 99.53% 2
Montana 82,832 55,382 66.86% 30
Nebraska 210,235 169,982 80.85% 19
Nevada 172,274 141,936 82.39% 17
New Hampshire 111,559 83,529 74.87% 23
New Jersey 858,177 595,626 69.41% 27
New Mexico 400,835 261,318 65.19% 34
New York 4,208,629 2,572,242 61.12% 40
North Carolina 1,299,624 843,441 64.90% 35
North Dakota 54,063 30,069 55.62% 43
Ohio 1,749,120 698,049 39.91% 47
Oklahoma 556,068 477,677 85.90% 14
Oregon 408,932 369,447 90.34% 8
Pennsylvania 1,816,812 1,568,237 86.32% 13
Puerto Rico 930,989 907,236 97.45% 5
Rhode Island 181,483 119,483 65.84% 32
South Carolina 690,391 139,412 20.19% 48
South Dakota 101,006 99,240 98.25% 3
Tennessee 1,190,407 1,190,407 100.00% 1
Texas 2,767,930 1,897,394 68.55% 28
Utah 208,501 181,173 86.89% 10
Vermont 133,466 86,347 64.70% 36
Virgin Islands 5,262 0 0.00% 51
Virginia 704,739 445,560 63.22% 39
Washington 990,321 858,052 86.64% 11
West Virginia 296,831 137,457 46.31% 46
Wisconsin 863,145 403,306 46.73% 45
Wyoming 62,660 0 0.00% 51
State Medicaid enrollment includes individuals enrolled in State health care reform programs that expand eligibility beyond traditional Medicaid eligibility
standards. This table provides unduplicated figures for Medicaid Enrollment and Managed Care Enrollment by State for a single point in time. These
values differ significantly (i.e., are lower than) unduplicated annual counts of enrollees over the entire year.
Source: Medicaid Managed Care Enrollment Report: Summary Statistics as of June 30, 2006. DHHS, CMS, Center for Medicaid & State Operations.
2-31
National Pharmaceutical Council Pharmaceutical Benefits 2007
2-32
National Pharmaceutical Council Pharmaceutical Benefits 2007
State Medicaid enrollment includes individuals enrolled in State health care reform programs that expand eligibility beyond traditional Medicaid
eligibility standards.
Sources: Medicaid Managed Care Enrollment Report: Summary Statistics as of June 30, 2001; 2002; 2003; 2004; 2005; 2006. DHHS, CMS, Center
for Medicaid & State Operations.
2-33
National Pharmaceutical Council Pharmaceutical Benefits 2007
HIO=Health Insuring Organization; Commercial MCO=Commercial Managed Care Organization; Medicaid-only MCO=Medicaid-only
Managed Care Organization; PCCM=Primary Care Case Management; PIHP=Prepaid Inpatient Health Plan; PAHP=Prepaid Ambulatory Health
Plans; PACE=Program for All-Inclusive Care for the Elderly.
Source: Medicaid Managed Care Enrollment Report: Summary Statistics as of June 30, 2006. DHHS, CMS, Center for Medicaid & State
Operations.
2-34
National Pharmaceutical Council Pharmaceutical Benefits 2007
Source: Medicaid Managed Care Enrollment Report: Summary Statistics as of June 30, 2006. DHHS, CMS, Center for Medicaid & State
Operations.
2-35
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Individual State totals may not sum to total managed care enrollment (pages 2-29 and 2-31) because State totals include individuals enrolled in
more than one plan type, including dental, mental, and long-term care.
**Includes managed care entities whose structure is “other” and not considered a PCCM, MCO, PIHP, PAHP, or PACE.
Source: Medicaid Managed Care Enrollment Report: Summary Statistics as of June 30, 2006. DHHS, CMS, Center for Medicaid & State
Operation.
2-36
National Pharmaceutical Council Pharmaceutical Benefits 2007
Section 1915(b) waivers are granted to give States the authority to conduct Medicaid programs
outside of the scope of the Medicaid statute, allowing them to waive freedom of choice, statewide
access to care, and comparability requirements under Section 1902 of the Social Security Act. With a
1915(b) waiver, a State can require mandatory enrollment of Medicaid recipients in managed care
plans. Section 1915(b) waivers can also allow a State to create a “carveout” delivery system for
specialty care, e.g., a Managed Behavioral Health Care Plan. Section 1915(b) waivers cannot
negatively impact beneficiary access or quality of care of services, and must be cost-effective (i.e.,
cost must be less than the Medicaid program would cost without the waiver). Section 1915(b)
waivers are typically limited to a targeted geographical area or population, are approved for an initial
period of two years, and can be renewed on an ongoing basis if the State reapplies.
Four options for 1915(b) waivers exist; each is governed by a different subsection(s) of Section
1915(b);
! Paragraph (b)(1) - Case Management: States are allowed to implement case management
systems which can be as simple as requiring each beneficiary to choose a primary care
provider or as comprehensive as mandating enrollment in a prepaid health plan. The
Balanced Budget Act of 1997 also gave States the option to enroll certain beneficiaries
into managed care via a State Plan Amendment.
! Paragraph (b)(2) - Central Broker: Localities are allowed to act as a central broker in
assisting Medicaid eligibles in selecting among competing health care plans, if such a
restriction does not substantially impair access to medically necessary services of
adequate quality.
! Paragraph (b)(3) - Shared Cost Saving: States are allowed to share (through provision of
additional services) cost savings (resulting from use by the recipient of more cost-
effective medical care) with recipients of medical assistance under the State Plan.
! Paragraph (b)(4) - Restrict Providers: States can limit the number of providers of certain
services. These waivers are sometimes referred to as selective contracting waivers and
are gaining in popularity. For example, some approved 1915(b)(4) waivers include
programs to restrict the number of providers of transportation services, organ transplants,
and inpatient obstetrical care.
Although Section 1915(b) waivers allow States to increase access to managed care plans, States are still
limited under Federal regulations and cannot use them to serve beneficiaries beyond Medicaid State Plan
Eligibility or change their benefits package. In order to expand their Medicaid programs even further
than under Section 1915(b) waivers, States apply for Section 1115 research and demonstration waivers.
2-37
National Pharmaceutical Council Pharmaceutical Benefits 2007
Section 1115 research and demonstration waivers release States from standard Medicaid
requirements, allowing them the flexibility to test substantially new ideas of policy merit. Along with
Section 1915(b) waivers, Section 1115 waivers allow States to waive freedom of choice, statewide
access to care, and comparability requirements. However, a Section 1115 waiver also allows States
to provide new and additional services, test new payment methods, offer benefits to new and
expanded populations, and contract with managed care organizations that do not meet the necessary
criteria of Section 1903 of the Social Security Act.
To receive approval of a Section 1115 waiver, States submit a proposal to CMS for discussion and
review. Once operational, States allow formal evaluations of the research and public policy value of
the programs and to demonstrate that their programs do not exceed costs, which would have
otherwise occurred under traditional Medicaid programs (i.e., States must demonstrate budget
neutrality). Section 1115 waivers are usually granted for a five-year period and each State must
submit a request for continuation. For example, Arizona has operated its program under a Section
1115 waiver for over 20 years. The Benefits Improvement and Protection Act (BIPA) of 2000
streamlined the process for States to submit requests for and receive extensions of Section 1115
demonstration waivers.
Section 1115 demonstration authority may be used to extend pharmacy coverage to certain low-
income elderly and disabled individuals who are not otherwise eligible for Medicaid. This type of
Section 1115 waiver program is commonly referred to as “Pharmacy Plus.” Its purpose is to provide
a subsidized pharmacy benefit that is intended to assist individuals in maintaining their healthy status
and avoid spending down to Medicaid income and asset eligibility levels. The waivers will test how
provision of a pharmacy benefit to a non-Medicaid covered population will affect Medicaid costs,
utilization and future eligibility trends.
2-38
National Pharmaceutical Council Pharmaceutical Benefits 2007
Date Originally
State Official Program Name Waiver Authority
Approved
Arkansas Arkansas Safety Net Benefit Program HIFA 1115 1115 03/03/2006
2-39
National Pharmaceutical Council Pharmaceutical Benefits 2007
Date Originally
State Official Program Name Waiver Authority
Approved
District of Columbia District of Columbia 1115 for Childless Adults 1115 03/07/2002
2-40
National Pharmaceutical Council Pharmaceutical Benefits 2007
Date Originally
State Official Program Name Waiver Authority
Approved
2-41
National Pharmaceutical Council Pharmaceutical Benefits 2007
Date Originally
State Official Program Name Waiver Authority
Approved
Indiana Indiana Family Planning 1115 Demonstration 1115 Family Planning Pending
Louisiana Louisiana Family Planning Waiver 1115 1115 Family Planning 06/06/2006
2-42
National Pharmaceutical Council Pharmaceutical Benefits 2007
Date Originally
State Official Program Name Waiver Authority
Approved
Missouri Missouri Family Planning 1115 Waiver 1115 Family Planning Under Review
Montana Montana Basic Medicaid for Able Bodied Adults 1115 01/30/2004
New Mexico New Mexico Family Planning 1115 Family Planning 08/01/1997
2-43
National Pharmaceutical Council Pharmaceutical Benefits 2007
Date Originally
State Official Program Name Waiver Authority
Approved
North Carolina North Carolina Family Planning 1115 1115 Family Planning 11/05/2004
2-44
National Pharmaceutical Council Pharmaceutical Benefits 2007
Date Originally
State Official Program Name Waiver Authority
Approved
South Carolina South Carolina Hurricane Katrina Relief 1115 Katrina 10/20/2005
2-45
National Pharmaceutical Council Pharmaceutical Benefits 2007
Date Originally
State Official Program Name Waiver Authority
Approved
West Virginia West Virginia Mountain Health Trust 1915(b) 1915(b) 04/29/1996
West Virginia West Virginia Dental and Vision Waiver 1115 Pending
2-46
National Pharmaceutical Council Pharmaceutical Benefits 2007
Section 3:
State Characteristics
3-1
National Pharmaceutical Council Pharmaceutical Benefits 2007
3-2
National Pharmaceutical Council Pharmaceutical Benefits 2007
STATE CHARACTERISTICS
Presented in Section 3 of the Compilation is State-by-State information on several topics. The
Section begins with a series of tables showing select State demographic characteristics including
age composition and racial/Hispanic status. Next, insurance coverage, poverty status,
employment, and income data for each State are presented. The final group of tables show select
components of each State’s health care system including Medicare and Medicaid certified
facilities (hospitals, SNFs, ICFs/MR, home health agencies, and rural health clinics), licensed
pharmacies, and health manpower (physicians, Registered Nurses, and pharmacists).
The data in Section 3 have been compiled from a myriad of sources. These include:
! CMS
! The U.S. Bureau of the Census
! The Bureau of Labor Statistics (BLS)
! The Health Resources and Services Administration (HRSA)
! The National Association of Boards of Pharmacy
Because of the unevenness with which the various government agencies and other organizations
have released updated information, we have carefully reviewed all possible information sources
and made judgments on which data to present. In the final analysis, we have included those data
that, in our opinion, best reflect the factors and characteristics on which we have reported.
However, certain limitations in the different sources have resulted in some inconsistencies among
the tables. The following examples illustrate this problem.
The table showing the age distribution of the population is derived from the 2006 American
Community Survey conducted by the U.S. Bureau of the Census. Unfortunately, individuals
residing in “group quarters” are not included in this survey. Hence, the total population figure
(and the corresponding figures for each State) presented in this table is inconsistent with the
population total in the table showing insurance status.
The data on insurance status was compiled from the Current Population Survey, 2006 Annual
Social and Economic Supplement, a collaborative effort by the Census Bureau and BLS. Hence,
the estimates on the number of Medicare and Medicaid beneficiaries differ slightly from those
published by CMS. In addition, more detailed data on poverty, also compiled from the 2006
Annual Social and Economic Supplement to the Current Population Survey, have been included in
this year’s Compilation.
HRSA’s Bureau of Health Professions, National Center for Health Workforce Analysis is
responsible for compiling the Area Resource File (ARF), an important annual data file for
researchers, planners, policymakers, and others seeking information on the health professions
workforce, health care facilities, health care utilization and expenditures, etc. at a variety of
geographic levels. Physician data come from the 2007 ARF. Nursing data come from HRSA’s
2004 National Sample Survey of Registered Nurses, the most comprehensive source of statistics
on individuals with active registered nurse licenses in the U.S., whether or not they are currently
employed in nursing.
Despite the limitations confronted while compiling these statistics, we believe that the data
presented in Section 3 provide a useful and meaningful picture of State characteristics. Users of
the Compilation are urged to carefully read the source information and notes at the bottom of each
table in order to understand the limitations of the data contained therein.
3-3
National Pharmaceutical Council Pharmaceutical Benefits 2007
3-4
National Pharmaceutical Council Pharmaceutical Benefits 2007
3-5
National Pharmaceutical Council Pharmaceutical Benefits 2007
3-6
National Pharmaceutical Council Pharmaceutical Benefits 2007
Source: U.S. Department of Commerce, Bureau of the Census, 2006 Population Estimates.
3-7
National Pharmaceutical Council Pharmaceutical Benefits 2007
3-8
National Pharmaceutical Council Pharmaceutical Benefits 2007
% Covered by % Covered by
Total % Covered by % Covered by Military Private
State Population Medicaid Medicare Insurance Insurance % Not Insured
National Total 296,824,000 12.9% 13.6% 3.6% 67.9% 15.8%
Alabama 4,532,000 13.5% 15.1% 4.9% 68.6% 15.2%
Alaska 659,000 12.1% 8.8% 13.8% 64.9% 16.5%
Arizona 6,269,000 16.1% 12.7% 4.2% 60.1% 20.9%
Arkansas 2,758,000 15.3% 15.0% 4.9% 60.3% 18.9%
California 36,208,000 15.9% 11.0% 2.6% 62.9% 18.8%
Colorado 4,803,000 8.8% 10.3% 4.0% 70.6% 17.2%
Connecticut 3,462,000 11.7% 14.4% 2.7% 76.2% 9.4%
Delaware 862,000 9.5% 15.1% 4.9% 73.9% 12.2%
District of Columbia 569,000 20.6% 11.4% 2.1% 67.0% 11.6%
Florida 18,062,000 9.9% 17.1% 5.4% 62.7% 21.2%
Georgia 9,347,000 12.3% 10.5% 5.8% 65.1% 17.7%
Hawaii 1,255,000 10.6% 13.5% 9.6% 74.7% 8.8%
Idaho 1,475,000 11.7% 13.6% 3.8% 69.1% 15.4%
Illinois 12,644,000 10.9% 12.4% 1.6% 72.8% 14.0%
Indiana 6,337,000 10.1% 13.0% 2.9% 75.3% 11.8%
Iowa 2,919,000 14.1% 14.8% 2.8% 75.9% 10.5%
Kansas 2,723,000 11.8% 14.9% 3.3% 74.7% 12.3%
Kentucky 4,106,000 14.7% 14.7% 3.9% 66.7% 15.6%
Louisiana 4,212,000 15.6% 15.6% 2.3% 58.6% 21.9%
Maine 1,315,000 17.9% 17.9% 5.2% 70.6% 9.3%
Maryland 5,613,000 8.4% 8.4% 4.4% 75.0% 13.8%
Massachusetts 6,335,000 13.1% 13.1% 1.3% 74.0% 10.4%
Michigan 9,970,000 13.1% 13.1% 1.6% 74.7% 10.5%
Minnesota 6,149,000 9.8% 11.3% 2.0% 65.4% 7.7%
Mississippi 2,892,000 17.2% 14.7% 4.6% 59.2% 20.7%
Missouri 5,800,000 11.7% 16.4% 3.0% 70.9% 13.3%
Montana 931,000 11.6% 14.8% 5.2% 67.7% 17.2%
Nebraska 1,767,000 8.6% 13.3% 6.6% 75.0% 12.3%
Nevada 2,535,000 6.9% 13.2% 4.0% 66.4% 19.6%
New Hampshire 1,309,000 6.7% 14.0% 3.2% 70.1% 11.5%
New Jersey 8,660,000 7.8% 13.0% 1.0% 73.5% 15.5%
New Mexico 1,943,000 15.9% 14.1% 5.9% 55.6% 22.9%
New York 19,040,000 18.6% 14.5% 1.0% 13.9% 14.0%
North Carolina 8,851,000 13.4% 14.3% 3.9% 64.6% 17.9%
North Dakota 617,000 8.8% 13.3% 3.2% 76.7% 12.2%
Ohio 11,319,000 14.1% 14.1% 3.1% 73.7% 10.1%
Oklahoma 3,492,000 12.7% 14.8% 7.8% 61.4% 18.9%
Oregon 3,715,000 10.8% 13.6% 2.9% 68.2% 17.9%
Pennsylvania 12,345,000 11.9% 16.1% 1.3% 75.1% 9.7%
Rhode Island 1,054,000 21.1% 14.2% 2.7% 73.4% 8.6%
South Carolina 4,226,000 14.2% 15.3% 5.5% 65.0% 15.9%
South Dakota 77,000 10.6% 15.6% 6.8% 73.7% 11.8%
Tennessee 5,920,000 13.8% 15.5% 6.6% 66.2% 13.7%
Texas 23,236,000 12.2% 12.2% 3.4% 59.3% 24.5%
Utah 2,537,000 9.3% 9.5% 2.9% 71.9% 17.4%
Vermont 620,000 18.5% 14.4% 2.9% 71.3% 10.2%
Virginia 7,538,000 7.5% 12.0% 10.5% 72.1% 13.3%
Washington 6,318,000 12.6% 13.1% 7.3% 72.7% 11.8%
West Virginia 1,814,000 17.3% 18.8% 4.5% 64.0% 13.5%
Wisconsin 5,476,000 11.7% 13.2% 2.6% 77.1% 8.8%
Wyoming 516,000 8.9% 15.3% 6.2% 73.3% 14.5%
*The sum of rows may be greater than the total State population because individuals may have dual coverage and appear in
more than one category.
Source: U.S. Department of Commerce, Bureau of the Census, Current Population Survey, 2007 Annual Social and Economic
Supplement.
3-9
National Pharmaceutical Council Pharmaceutical Benefits 2007
Source: U.S. Department of Commerce, Bureau of the Census, Current Population Survey, 2007 Annual Social and
Economic Supplement.
3-10
National Pharmaceutical Council Pharmaceutical Benefits 2007
Source: U.S. Department of Commerce, Bureau of the Census, Current Population Survey, 2007 Annual Social and
Economic Supplement.
3-11
National Pharmaceutical Council Pharmaceutical Benefits 2007
3-12
National Pharmaceutical Council Pharmaceutical Benefits 2007
Sources: OSCAR Report 10. Facility Counts: Active Providers. CMS, Center for Medicaid and State Operations, August 1,
2007 (hospitals and rural health clinics); http://www.cms.hhs.gov/HealthPlanRepFileData/05_Inst.asp (SNF and ICF-MR);
http://www.medicare.gov/Download/DownloadDB.asp (Home Health Compare).
3-13
National Pharmaceutical Council Pharmaceutical Benefits 2007
3-14
National Pharmaceutical Council Pharmaceutical Benefits 2007
LEGEND
3-15
National Pharmaceutical Council Pharmaceutical Benefits 2007
Physicians, 2005
Primary Care
Office Based Physicians Percent
Physicians Physicians Physicians (Non-Federal, Office Based
(Non-Federal, Per 1,000 (Non-Federal, Percent Patient Care, Physicians
State Patient Care) Population Patient Care) Office Based Office Based)* Primary Care
National Total 690,592 2.3 554,482 80% 287,322 42%
Alabama 8,802 1.9 7,288 83% 3,953 45%
Alaska 1,286 1.9 1,181 92% 851 66%
Arizona 10,962 1.8 9,522 87% 4,756 43%
Arkansas 5,102 1.8 4,257 83% 2,668 52%
California 82,591 2.3 70,273 85% 36,665 44%
Colorado 10,653 2.3 9,155 86% 5,050 47%
Connecticut 10,989 3.1 8,424 77% 3,650 33%
Delaware 1,863 2.2 1,514 81% 749 40%
District of Columbia 3,395 5.8 2,240 66% 899 26%
Florida 38,575 2.2 33,796 88% 15,809 41%
Georgia 17,583 1.9 14,921 85% 7,976 45%
Hawaii 3,380 2.7 2,922 86% 1,539 46%
Idaho 2,237 1.6 2,086 93% 1,340 60%
Illinois 30,715 2.4 23,408 76% 12,575 41%
Indiana 12,249 1.8 10,218 83% 5,877 48%
Iowa 4,838 1.6 3,894 80% 2,463 51%
Kansas 5,431 2.0 4,486 83% 2,679 49%
Kentucky 8,645 2.1 7,248 84% 3,941 46%
Louisiana 10,332 2.3 8,257 80% 4,120 40%
Maine 3,145 2.4 2,656 84% 1,561 50%
Maryland 18,222 3.3 14,215 78% 6,403 35%
Massachusetts 24,236 3.8 17,485 72% 7,544 31%
Michigan 21,522 2.1 16,210 75% 8,726 41%
Minnesota 12,938 2.5 10,386 80% 6,938 54%
Mississippi 4,618 1.6 3,855 83% 2,162 47%
Missouri 12,242 2.1 9,400 77% 4,562 37%
Montana 1,904 2.0 1,763 93% 1,071 56%
Nebraska 3,772 2.1 2,996 79% 1,929 51%
Nevada 4,089 1.7 3,721 91% 1,923 47%
New Hampshire 3,084 2.4 2,594 84% 1,449 47%
New Jersey 23,821 2.7 18,868 79% 8,342 35%
New Mexico 3,941 2.0 3,259 83% 1,992 51%
New York 64,498 3.3 44,677 69% 19,534 30%
North Carolina 19,195 2.2 15,760 82% 8,494 44%
North Dakota 1,377 2.2 1,160 84% 768 56%
Ohio 26,420 2.3 20,203 76% 10,637 40%
Oklahoma 5,405 1.5 4,514 84% 2,508 46%
Oregon 8,575 2.4 7,449 87% 4,245 50%
Pennsylvania 31,516 2.5 23,548 75% 11,102 35%
Rhode Island 3,363 3.1 2,478 74% 1,142 34%
South Carolina 8,804 2.1 7,255 82% 4,087 46%
South Dakota 1,501 1.9 1,327 88% 835 56%
Tennessee 14,031 2.4 11,710 83% 6,182 44%
Texas 42,896 1.9 35,459 83% 18,666 44%
Utah 4,609 1.9 3,805 83% 2,075 45%
Vermont 1,961 3.2 1,479 75% 932 48%
Virginia 17,556 2.3 14,363 82% 7,948 45%
Washington 14,458 2.3 12,462 86% 7,526 52%
West Virginia 3,666 2.0 2,860 78% 1,588 43%
Wisconsin 12,730 2.3 10,688 84% 6,376 50%
Wyoming 869 1.7 787 91% 515 59%
*Primary care physicians include General Practice, General Family Practice, General Internal Medicine, Ob-Gyn, and General Pediatrics.
Source: USDHHS, HRSA, Bureau of Health Professions, National Center for Health Workforce Information & Analysis, Area Resource File,
June 2007.
3-16
National Pharmaceutical Council Pharmaceutical Benefits 2007
# FTE # FTE
Registered Registered Nurses* Pharmacists** Pharmacists**
State Nurses* per 1,000 population (Licensed by State) per 1,000 population
National Total 2,056,960 7.0 372,032 1.2
Alabama 31,736 7.0 7,596 1.7
Alaska 5,839 8.9 660 1.0
Arizona 35,036 5.7 7,672 1.2
Arkansas 18,318 6.7 3,920 1.4
California 175,183 4.9 33,922 0.9
Colorado 29,268 6.4 5,807 1.2
Connecticut 26,698 7.6 4,637 1.3
Delaware 7,194 8.7 1,479 1.7
District of Columbia 10,194 17.6 1,341 2.3
Florida 117,447 6.8 21,540 1.2
Georgia 58,910 6.6 11,284 1.2
Hawaii 7,978 6.3 1,660 1.3
Idaho 7,401 5.3 1,722 1.2
Illinois 95,490 7.5 14,458 1.1
Indiana 46,677 7.5 8,481 1.3
Iowa 27,451 9.3 5,156 1.7
Kansas 21,328 7.8 3,709 1.3
Kentucky 33,435 8.1 5,713 1.4
Louisiana 32,183 7.2 6,375 1.5
Maine 12,799 9.7 1,546 1.2
Maryland 39,725 7.2 7,820 1.4
Massachusetts 59,337 9.2 9,902 1.5
Michigan 70,630 7.0 11,322 1.1
Minnesota 40,454 7.9 6,484 1.3
Mississippi 21,768 7.5 3,483 1.2
Missouri 49,174 8.5 7,486 1.3
Montana 6,520 7.0 1,639 1.7
Nebraska 15,990 9.2 3,004 1.7
Nevada 12,733 5.5 8,475 3.4
New Hampshire 13,669 10.5 2,073 1.6
New Jersey 59,691 6.9 13,927 1.6
New Mexico 11,811 6.2 2,379 1.2
New York 148,653 7.7 19,798 1.0
North Carolina 68,030 8.0 10,494 1.2
North Dakota 6,391 10.1 2,122 3.3
Ohio 93,830 8.2 15,185 1.3
Oklahoma 21,651 6.1 4,953 1.4
Oregon 24,459 6.8 4,125 1.1
Pennsylvania 106,912 8.6 18,707 1.5
Rhode Island 9,133 8.5 1,906 1.8
South Carolina 26,921 6.4 5,824 1.3
South Dakota 7,857 10.2 1,504 1.9
Tennessee 48,252 8.2 7,588 1.3
Texas 129,442 5.7 22,723 1.0
Utah 13,056 5.4 2,358 0.9
Vermont 5,006 8.1 885 1.4
Virginia 47,904 6.4 9,142 1.2
Washington 38,740 6.2 7,541 1.2
West Virginia 14,125 7.8 3,024 1.7
Wisconsin 40,954 7.4 6,433 1.2
Wyoming 3,577 7.1 1,048 2.0
*FTE- Full-time equivalent employees as of 2004. Excludes 4,261 RNs for whom full-time/part-time status is unknown.
**As of June 30, 2006
Source: USDHHS, HRSA, Bureau of Health Professions, National Center for Health Workforce Information & Analysis, 2004 National
Sample Survey of Registered Nurses. 2007 National Association of Boards of Pharmacy, Survey of Pharmacy Law.
3-17
National Pharmaceutical Council Pharmaceutical Benefits 2007
3-18
National Pharmaceutical Council Pharmaceutical Benefits 2007
Section 4:
Pharmacy Program
Characteristics
4-1
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-2
National Pharmaceutical Council Pharmaceutical Benefits 2007
The Medicaid program defines prescribed drugs as simple or compound substances or mixtures of
substances prescribed for the cure, mitigation, or prevention of disease, or for health maintenance,
which are prescribed by a physician or other licensed practitioner of the healing arts within the scope
of their professional practice (42 CFR 440.120). The drugs must be dispensed by licensed authorized
practitioners on a written prescription that is recorded and maintained in the pharmacist’s or the
practitioner’s records.
On July 31, 1987, CMS published a notice of the final rule for limits on payments for drugs in the
Medicaid program. The regulations adopted in the rule became effective October 29, 1987 (52 FR
28648). In this final rule, CMS attempted to (1) respond to public comments on the NPRM (51 FR
2956); (2) provide maximum flexibility to the States in their administration of the Medicaid program;
(3) provide responsible but not burdensome Federal oversight of the Medicaid program; and (4) take
advantage of savings in the marketplace for multiple-source drugs.
To accomplish this, CMS adopted a Federal upper limit standard for certain multiple-source drugs,
based on application of a specific formula. The upper limit for other drugs is similar, in that it retains
the estimated acquisition cost (EAC) as the upper limit standard that State agencies must meet.
However, this standard is applied on an aggregate basis rather than on a prescription-specific basis.
State agencies are therefore encouraged to exercise maximum flexibility in establishing their own
payment methods (see the Federal Register, Vol. 52, No. 147, Friday, July 31, 1987, page 28648).
Multiple-Source Drugs
A multiple-source drug is one that is marketed or sold by two or more manufacturers or labelers, or a
drug marketed or sold by the same manufacturer or labeler under two or more different proprietary
names or under a proprietary name and without such a name.
A specific upper limit for a multiple-source drug may be established if the following requirements are
met:
! All of the formulations of the drug approved by the Food and Drug Administration (FDA) have
been evaluated as therapeutically equivalent in the current edition of the publication, Approved
Drug Products with Therapeutically Equivalent Evaluations; and
! At least three suppliers list the drug (which is classified by the FDA as Category A in its
publication) in the current editions of published compendia of cost information for drugs
available for sale nationally.
The upper limit for a multi-source drug for which a specific limit has been established does not apply
if a physician certifies in his or her own handwriting that a specific brand is “medically necessary” for
a particular recipient.
The handwritten phrase “brand necessary,” “medically necessary,” or “brand medically necessary”
must appear on the face of the prescription. The rule specifically states that a check-off box on a
prescription form is not acceptable, but it does not address the use of two-line prescription forms.
4-3
National Pharmaceutical Council Pharmaceutical Benefits 2007
The formula to be used in calculating the aggregate upper limit of payment for certain multiple-source
drugs will be 150% of the least costly therapeutic equivalent that can be purchased by pharmacists in
quantities of 100 tablets or capsules (or if the drug is not commonly available in quantities of 100, the
package size commonly listed), or in the case of liquids, the commonly listed size, plus a reasonable
dispensing fee.
Other Drugs
A drug described as an “other drug” is (1) a brand name drug certified as medically necessary by the
physician, (2) a multiple-source drug not subject to the 150% formula; or (3) a single-source drug.
Payments for these drugs must not exceed, in the aggregate, payment levels determined by applying
the lower of:
Other Requirements
The rule requires States to submit a State plan that describes their payment methods for prescribed
drugs. The rule does not prescribe a preferred payment method, as long as the State’s aggregate
spending in each category is equal to or below the upper limit requirements. States are also required
to submit assurances to CMS that the requirements are met.
The rule does not prescribe a preferred payment method for the States, but gives States the flexibility
to determine how they will pay for prescription drugs under Medicaid. As long as the State’s
aggregate spending is at or below the amount derived from the formula, the State is free to maintain
its current payment program or adopt other methods. States can alter payment rates for individual
drugs, balancing payment increases for certain products with payment decreases for other drugs so
that, in the aggregate, the program does not exceed the established limit. With the establishment of
upper limit payment maximums, some States may alter their current payment methods to comply with
the established limits.
State programs vary, depending upon whether or not State maximum allowable cost (MAC) programs
cover the same drugs listed by CMS. States with established MAC programs may be unaffected if
their MAC rates are already low, or they may have to make certain adjustments in their MAC levels
to meet the Federal aggregate expenditure limits. States without MAC programs may develop a new
payment method to increase the use of lower cost generic drug products in order to stay within the
upper payment limits, or may simply adopt CMS’ formula for listed drug products.
DRUG RECIPIENTS
Drug recipients are defined as individuals who received drugs, not as everyone eligible to receive
drugs. Today, all 50 States and the District of Columbia cover drugs under the Medicaid program.
4-4
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-5
National Pharmaceutical Council Pharmaceutical Benefits 2007
% of 2005 National
2005 2005 Medicaid Drug 2004 2004
State Payments Ranking Expenditures Payments Ranking
National Total $43,077,457,835 $40,065,314,592
New York $5,253,655,620 1 12.2% $4,782,579,851 2
California $5,187,275,034 2 12.0% $4,817,590,501 1
Florida $2,503,151,114 3 5.8% $2,472,756,351 3
Texas $2,416,879,360 4 5.6% $2,202,097,688 4
Tennessee $2,344,351,015 5 5.4% $2,196,066,176 5
Ohio $1,981,230,721 6 4.6% $1,819,580,108 6
North Carolina $1,790,399,967 7 4.2% $1,575,005,070 8
Illinois $1,716,361,486 8 4.0% $1,751,647,987 7
Missouri $1,246,144,317 9 2.9% $1,119,655,471 10
Georgia $1,184,915,057 10 2.8% $1,213,833,584 9
New Jersey $1,158,553,486 11 2.7% $1,016,646,964 11
Louisiana $1,082,597,269 12 2.5% $944,175,123 13
Massachusetts $1,067,378,270 13 2.5% $987,294,716 14
Pennsylvania $1,009,804,038 14 2.3% $952,341,486 12
Michigan $965,368,582 15 2.2% $874,729,802 15
Kentucky $794,519,116 16 1.8% $802,700,636 16
Wisconsin $759,682,514 17 1.8% $684,912,153 18
Indiana $751,525,376 18 1.7% $703,941,201 17
South Carolina $716,694,085 19 1.7% $673,035,838 19
Washington $682,553,233 20 1.6% $649,265,744 21
Mississippi $665,504,688 21 1.5% $668,097,090 20
Virginia $634,701,038 22 1.5% $582,093,270 23
Alabama $606,578,572 23 1.4% $594,477,767 22
Maryland $578,238,275 24 1.3% $490,288,888 24
Oklahoma $500,420,840 25 1.2% $416,314,217 26
Connecticut $496,715,211 26 1.2% $448,164,399 25
Minnesota $441,908,835 27 1.0% $394,600,158 27
West Virginia $431,614,161 28 1.0% $376,426,405 29
Arkansas $419,350,865 29 1.0% $380,446,105 28
Iowa $412,274,229 30 1.0% $371,927,390 30
Kansas $296,283,292 31 0.7% $274,203,278 33
Colorado $285,371,981 32 0.7% $264,117,222 31
Maine $282,039,741 33 0.7% $281,693,429 32
Oregon $261,373,083 34 0.6% $245,180,310 34
Nebraska $228,576,569 35 0.5% $231,317,773 35
Utah $221,854,365 36 0.5% $192,093,154 36
Vermont $184,730,219 37 0.4% $160,039,523 38
Rhode Island $173,884,102 38 0.4% $166,067,772 37
Idaho $168,780,832 39 0.4% $153,351,334 39
Nevada $134,564,289 40 0.3% $127,920,160 41
New Hampshire $133,253,555 41 0.3% $128,552,504 40
Alaska $127,315,710 42 0.3% $115,273,427 43
Delaware $122,026,857 43 0.3% $122,552,631 45
Hawaii $119,852,050 44 0.3% $117,149,907 44
New Mexico $116,252,520 45 0.3% $117,451,186 42
District of Columbia $105,948,589 46 0.2% $106,453,411 46
Montana $105,154,540 47 0.2% $99,334,048 47
South Dakota $88,963,445 48 0.2% $81,936,507 48
North Dakota $64,157,312 49 0.1% $59,722,091 49
Wyoming $51,242,060 50 0.1% $52,845,063 50
Arizona $5,486,350 51 0.0% $5,367,723 51
*Rebates have not been subtracted from these figures.
4-6
National Pharmaceutical Council Pharmaceutical Benefits 2007
Total Medicaid
Net Medical Assistance Total Drug % of Total
State Expenditures Expenditures* Net Expenditures
National Total $299,659,808,819 $43,077,457,835 14.4%
Alabama $3,837,473,614 $606,578,572 15.8%
Alaska $983,488,511 $127,315,710 12.9%
Arizona $5,725,919,558 $5,486,350 0.1%
Arkansas $2,809,920,508 $419,350,865 14.9%
California $33,662,911,379 $5,187,275,034 15.4%
Colorado $2,796,729,720 $285,371,981 10.2%
Connecticut $4,027,599,803 $496,715,211 12.3%
Delaware $868,667,588 $122,026,857 14.0%
District of Columbia $1,254,159,659 $105,948,589 8.4%
Florida $13,218,246,322 $2,503,151,114 18.9%
Georgia $7,333,266,041 $1,184,915,057 16.2%
Hawaii $1,033,126,200 $119,852,050 11.6%
Idaho $1,008,634,738 $168,780,832 16.7%
Illinois $10,785,542,795 $1,716,361,486 15.9%
Indiana $5,234,229,575 $751,525,376 14.4%
Iowa $2,376,772,384 $412,274,229 17.3%
Kansas $1,967,790,699 $296,283,292 15.1%
Kentucky $4,253,083,096 $794,519,116 18.7%
Louisiana $5,313,395,456 $1,082,597,269 20.4%
Maine $2,242,388,876 $282,039,741 12.6%
Maryland $5,136,302,340 $578,238,275 11.3%
Massachusetts $9,556,863,877 $1,067,378,270 11.2%
Michigan $8,656,266,850 $965,368,582 11.2%
Minnesota $5,528,371,422 $441,908,835 8.0%
Mississippi $3,342,615,012 $665,504,688 19.9%
Missouri $6,528,988,350 $1,246,144,317 19.1%
Montana $696,069,297 $105,154,540 15.1%
Nebraska $1,377,175,781 $228,576,569 16.6%
Nevada $1,184,065,213 $134,564,289 11.4%
New Hampshire $1,244,582,951 $133,253,555 10.7%
New Jersey $7,508,874,058 $1,158,553,486 15.4%
New Mexico $2,363,669,655 $116,252,520 4.9%
New York $42,752,347,265 $5,253,655,620 12.3%
North Carolina $8,844,879,833 $1,790,399,967 20.2%
North Dakota $508,464,760 $64,157,312 12.6%
Ohio $11,572,449,325 $1,981,230,721 17.1%
Oklahoma $2,712,779,961 $500,420,840 18.4%
Oregon $2,810,667,717 $261,373,083 9.3%
Pennsylvania $15,786,514,016 $1,009,804,038 6.4%
Rhode Island $1,671,398,242 $173,884,102 10.4%
South Carolina $4,068,509,449 $716,694,085 17.6%
South Dakota $608,250,647 $88,963,445 14.6%
Tennessee $7,557,403,733 $2,344,351,015 31.0%
Texas $17,264,066,130 $2,416,879,360 14.0%
Utah $1,341,242,046 $221,854,365 16.5%
Vermont $859,483,644 $184,730,219 21.5%
Virginia $4,425,080,633 $634,701,038 14.3%
Washington $5,700,850,706 $682,553,233 12.0%
West Virginia $2,161,356,254 $431,614,161 20.0%
Wisconsin $4,751,656,671 $759,682,514 16.0%
Wyoming $405,216,459 $51,242,060 12.6%
*Rebates have not been subtracted from these figures.
4-7
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-8
National Pharmaceutical Council Pharmaceutical Benefits 2007
Hormones and
Central Nervous Cardiovascular Anti-Infective Gastrointestinal Synthetic
State System Drugs Drugs Agents Drugs Substitutes
National Total $13,300,359,808 $3,969,414,844 $3,648,306,434 $2,469,562,269 $3,274,866,917
Alabama $208,760,996 $69,043,166 $60,931,002 $35,879,041 $62,771,380
Alaska $47,912,513 $9,505,258 $10,076,774 $10,087,697 $9,000,355
Arizona*
Arkansas $155,702,637 $38,171,834 $41,975,653 $19,069,811 $43,560,568
California $1,610,536,923 $630,157,032 $421,979,467 $378,449,383 $493,683,362
Colorado $122,978,421 $26,900,240 $22,474,930 $14,187,562 $25,233,231
Connecticut $198,383,506 $50,937,823 $36,772,205 $36,272,702 $32,042,343
Delaware $41,021,683 $11,732,238 $17,612,565 $3,126,934 $11,315,099
District of Columbia $26,670,897 $12,520,390 $23,179,899 $2,643,629 $6,592,102
Florida $747,292,514 $270,773,916 $363,341,806 $198,477,510 $191,344,602
Georgia $407,156,598 $120,487,467 $147,835,763 $55,381,643 $116,295,273
Hawaii $43,073,550 $17,937,928 $8,511,363 $4,330,362 $11,541,866
Idaho $71,352,803 $11,207,631 $10,474,850 $8,530,670 $14,690,005
Illinois**
Indiana $329,400,563 $63,864,597 $51,774,597 $37,105,204 $65,429,310
Iowa $180,751,055 $32,264,220 $30,515,629 $22,760,834 $34,717,131
Kansas $130,448,685 $23,299,032 $19,290,087 $22,768,014 $23,256,463
Kentucky $299,579,345 $89,039,723 $73,109,907 $41,944,307 $83,980,921
Louisiana $289,784,312 $93,920,065 $115,974,399 $64,822,495 $80,944,494
Maine $119,962,268 $28,225,919 $19,041,538 $28,918,551 $27,272,891
Maryland $223,828,886 $59,018,665 $40,017,606 $33,385,048 $32,668,403
Massachusetts $437,346,870 $94,472,294 $93,663,246 $72,171,009 $80,120,349
Michigan $447,139,945 $81,118,326 $45,939,633 $46,444,308 $69,242,799
Minnesota $203,255,537 $24,499,964 $22,934,171 $29,259,476 $28,421,319
Mississippi $210,940,132 $101,240,783 $68,988,274 $36,686,079 $66,591,404
Missouri $471,964,290 $115,900,356 $95,050,827 $40,690,835 $105,701,660
Montana $45,102,777 $7,459,968 $6,150,907 $5,131,898 $8,361,839
Nebraska $105,213,526 $21,345,302 $17,889,099 $9,481,172 $22,289,480
Nevada $54,004,427 $11,892,140 $11,024,517 $4,638,057 $9,828,218
New Hampshire $64,375,785 $10,219,677 $6,549,308 $8,369,457 $11,012,547
New Jersey $341,505,598 $126,475,891 $110,144,283 $79,960,008 $75,482,040
New Mexico**
New York $1,477,360,243 $547,267,499 $733,035,427 $346,610,504 $425,428,586
North Carolina $543,405,555 $175,726,290 $140,877,989 $157,859,974 $139,958,047
North Dakota $29,044,762 $5,398,111 $3,944,563 $2,884,297 $5,367,993
Ohio $755,434,684 $184,869,267 $156,813,358 $122,914,780 $166,743,130
Oklahoma $172,393,633 $36,570,700 $41,689,442 $20,604,328 $41,918,694
Oregon $147,403,531 $15,273,079 $10,964,664 $8,939,913 $16,522,989
Pennsylvania $404,913,210 $110,273,064 $64,274,505 $96,565,142 $85,279,878
Rhode Island $71,998,124 $21,461,519 $11,163,274 $14,165,053 $13,220,350
South Carolina $241,712,165 $102,316,506 $71,166,206 $29,469,037 $78,905,290
South Dakota $35,494,580 $5,758,477 $7,020,500 $7,328,902 $7,696,219
Tennessee**
Texas $750,907,166 $229,611,591 $239,350,204 $128,549,116 $221,602,731
Utah $90,793,203 $13,103,636 $13,704,039 $14,269,056 $16,005,029
Vermont $20,380,595 $4,923,113 $3,924,394 $2,831,497 $4,837,757
Virginia $216,282,993 $74,189,057 $44,188,648 $52,170,367 $49,166,042
Washington $215,060,401 $51,783,776 $36,951,943 $44,456,162 $47,672,718
West Virginia $148,004,350 $45,398,113 $30,465,631 $22,502,144 $39,328,691
Wisconsin $321,759,763 $88,777,279 $41,226,534 $43,727,866 $66,809,859
Wyoming $22,563,808 $3,081,922 $4,320,808 $2,740,435 $5,011,460
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-9
National Pharmaceutical Council Pharmaceutical Benefits 2007
Unclassified Blood
Therapeutic Autonomic Formulation and
State Agents Drugs Coagulation Other Totals
National Average $1,268,709,776 $1,504,382,071 $1,780,432,781 $4,539,258,679 $35,755,293,579
Alabama $19,815,936 $28,276,590 $30,130,751 $93,636,378 $609,245,240
Alaska $4,236,261 $4,702,727 $7,297,448 $12,322,584 $115,141,617
Arizona*
Arkansas $15,089,745 $20,212,100 $22,302,405 $53,697,466 $409,782,219
California $154,643,546 $119,405,722 $273,003,668 $461,107,379 $4,542,966,482
Colorado $11,231,161 $14,098,886 $8,493,735 $34,949,118 $280,547,284
Connecticut $13,954,956 $17,727,053 $19,448,788 $48,084,018 $453,623,394
Delaware $4,397,712 $4,948,366 $5,145,925 $15,613,980 $114,914,502
District of Columbia $1,844,427 $2,118,470 $4,119,643 $11,970,077 $91,659,534
Florida $84,995,587 $102,867,469 $132,999,437 $303,067,303 $2,395,160,144
Georgia $44,108,288 $63,249,138 $60,174,610 $197,123,630 $1,211,812,410
Hawaii $5,706,853 $4,405,121 $7,303,532 $12,792,380 $115,602,955
Idaho $5,947,343 $6,458,100 $3,853,852 $16,587,939 $149,103,193
Illinois**
Indiana $29,725,442 $34,463,246 $61,441,511 $102,961,022 $776,165,492
Iowa $12,417,134 $18,409,947 $10,842,034 $43,851,314 $386,529,298
Kansas $8,849,086 $12,576,734 $9,873,381 $30,332,674 $280,694,156
Kentucky $31,804,260 $53,791,138 $37,300,733 $113,248,663 $823,798,997
Louisiana $30,168,868 $45,859,178 $48,365,184 $157,515,097 $927,354,092
Maine $9,405,074 $11,919,851 $11,623,735 $25,627,824 $281,997,651
Maryland $13,097,536 $13,898,001 $29,865,381 $42,225,645 $488,005,171
Massachusetts $28,219,888 $33,704,489 $38,426,993 $100,869,810 $978,994,948
Michigan $32,181,251 $32,307,939 $55,846,178 $91,605,196 $901,825,575
Minnesota $12,809,076 $14,795,693 $16,753,741 $40,961,946 $393,690,923
Mississippi $22,684,360 $33,882,763 $32,051,245 $89,074,230 $662,139,270
Missouri $38,296,575 $59,234,130 $55,920,224 $149,412,057 $1,132,170,954
Montana $4,261,207 $4,887,086 $3,064,524 $11,854,757 $96,274,963
Nebraska $8,939,346 $11,010,780 $8,419,450 $29,000,045 $233,588,200
Nevada $4,516,008 $5,936,937 $10,643,715 $15,284,714 $127,768,733
New Hampshire $4,110,542 $6,720,017 $2,965,942 $14,653,555 $128,976,830
New Jersey $35,679,895 $43,449,706 $65,546,285 $131,578,491 $1,009,822,197
New Mexico**
New York $182,586,702 $165,350,243 $229,409,543 $639,902,270 $4,746,951,017
North Carolina $54,413,248 $70,605,784 $70,282,003 $218,643,112 $1,571,772,002
North Dakota $2,464,988 $2,861,449 $1,682,198 $7,114,750 $60,763,111
Ohio $56,744,399 $101,205,281 $71,165,315 $240,076,427 $1,855,966,641
Oklahoma $17,396,906 $20,036,410 $23,059,956 $46,342,187 $420,012,256
Oregon $5,860,382 $8,296,626 $9,343,855 $16,214,738 $238,819,777
Pennsylvania $34,783,700 $60,401,478 $70,317,964 $131,016,175 $1,057,825,116
Rhode Island $5,242,264 $7,200,855 $5,771,722 $16,991,501 $167,214,662
South Carolina $26,550,002 $31,574,570 $32,393,334 $100,541,806 $714,628,916
South Dakota $3,172,046 $4,121,980 $3,312,522 $11,246,610 $85,151,836
Tennessee**
Texas $94,573,950 $96,244,690 $100,239,771 $370,863,735 $2,231,942,954
Utah $5,658,786 $7,456,053 $2,766,670 $19,584,825 $183,341,297
Vermont $2,045,354 $2,095,719 $1,828,575 $6,144,343 $49,011,347
Virginia $20,969,064 $28,697,738 $32,941,936 $77,399,118 $596,004,963
Washington $16,555,811 $17,206,755 $10,090,619 $50,041,660 $489,819,845
West Virginia $14,321,406 $17,966,680 $10,815,009 $45,634,292 $374,436,316
Wisconsin $29,817,176 $35,312,820 $30,347,538 $83,348,189 $741,127,024
Wyoming $2,416,229 $2,429,563 $1,440,201 $7,143,649 $51,148,075
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-10
National Pharmaceutical Council Pharmaceutical Benefits 2007
Hormones and
Central Nervous Cardiovascular Anti-Infective Gastrointestinal Synthetic
State System Drugs Drugs Agents Drugs Substitutes
National Average 167,888,750 79,371,749 44,019,700 33,525,189 53,642,322
Alabama 3,278,516 1,590,111 1,084,735 611,990 1,133,807
Alaska 584,955 237,819 120,430 111,598 160,090
Arizona*
Arkansas 1,940,172 872,682 789,138 289,294 735,854
California 16,140,871 8,762,370 4,163,569 3,826,736 6,211,702
Colorado 1,869,444 696,456 466,021 264,850 607,516
Connecticut 2,132,602 994,667 265,547 384,063 568,378
Delaware 538,520 208,070 168,827 69,670 179,106
District of Columbia 281,615 238,963 89,086 34,972 107,267
Florida 9,805,117 5,812,626 2,781,099 2,112,140 3,136,531
Georgia 5,909,547 2,729,143 2,417,822 989,503 2,179,471
Hawaii 490,293 336,920 89,324 142,354 176,389
Idaho 842,808 233,923 199,437 115,892 250,988
Illinois**
Indiana 4,392,459 1,552,226 910,144 928,081 1,141,298
Iowa 2,405,468 813,817 573,808 325,830 670,385
Kansas 1,551,388 591,586 353,575 268,149 475,833
Kentucky 4,645,620 2,073,878 1,366,167 1,089,815 1,444,433
Louisiana 3,938,337 1,856,000 1,607,037 642,164 1,335,519
Maine 2,015,551 770,556 347,931 351,711 586,256
Maryland 2,633,151 1,258,463 312,811 371,774 659,700
Massachusetts 5,812,606 2,421,077 974,401 937,398 1,610,341
Michigan 6,282,409 2,321,047 761,712 843,742 1,394,537
Minnesota 2,168,242 621,246 306,388 464,346 510,208
Mississippi 2,825,237 1,954,769 1,072,504 500,967 1,075,376
Missouri 5,780,979 2,584,837 1,255,130 918,442 1,789,360
Montana 579,675 180,716 120,309 95,081 171,680
Nebraska 1,382,247 484,928 375,678 322,118 406,308
Nevada 624,279 272,312 124,908 88,113 179,704
New Hampshire 887,305 249,895 141,013 175,189 203,533
New Jersey 3,964,285 2,369,974 706,224 846,406 1,209,970
New Mexico**
New York 16,651,586 9,648,142 4,963,852 4,298,342 5,976,807
North Carolina 6,812,234 3,684,497 1,937,463 1,455,037 2,452,646
North Dakota 375,058 153,187 83,016 51,875 119,577
Ohio 10,712,189 4,250,302 2,447,799 2,555,093 3,098,614
Oklahoma 2,106,058 749,897 758,715 319,697 648,626
Oregon 2,007,873 459,454 200,114 232,258 376,993
Pennsylvania 5,047,146 2,436,122 967,173 1,126,691 1,584,252
Rhode Island 870,717 346,964 117,378 175,104 206,611
South Carolina 3,143,775 2,208,842 964,823 489,627 1,436,448
South Dakota 422,113 155,469 142,829 75,437 142,546
Tennessee**
Texas 9,555,330 3,325,626 4,684,673 1,690,336 2,849,109
Utah 1,226,270 279,704 293,800 183,928 314,835
Vermont 249,031 100,613 50,198 39,517 78,797
Virginia 3,017,582 1,546,359 583,196 809,102 918,666
Washington 3,266,958 1,315,922 523,389 765,203 934,552
West Virginia 2,294,623 944,174 607,461 373,840 675,911
Wisconsin 4,160,520 2,605,992 663,934 718,305 1,439,276
Wyoming 265,989 69,406 85,112 43,409 76,516
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-11
National Pharmaceutical Council Pharmaceutical Benefits 2007
Unclassified Blood
Therapeutic Autonomic Formulation and
State Agents Drugs Coagulation Other Totals
National Average 12,858,711 30,249,413 13,374,644 110,167,864 545,098,342
Alabama 227,396 673,411 262,701 2,682,619 11,545,286
Alaska 36,707 93,014 33,986 256,715 1,635,314
Arizona*
Arkansas 146,838 357,751 139,053 1,361,082 6,631,864
California 1,257,486 2,430,679 1,591,923 9,951,195 54,336,531
Colorado 121,849 351,496 118,012 971,534 5,467,178
Connecticut 147,746 303,980 175,517 992,217 5,964,717
Delaware 39,080 108,626 33,781 350,778 1,696,458
District of Columbia 23,958 48,848 25,167 224,251 1,074,127
Florida 976,550 1,938,542 961,015 6,322,293 33,845,913
Georgia 477,858 1,397,467 489,393 4,840,641 21,430,845
Hawaii 69,406 82,720 47,561 326,396 1,761,363
Idaho 55,809 135,658 42,852 371,928 2,249,295
Illinois**
Indiana 252,246 707,340 331,131 2,723,249 12,938,174
Iowa 136,072 371,056 149,482 1,150,391 6,596,309
Kansas 95,197 248,781 98,869 820,171 4,503,549
Kentucky 350,381 977,033 384,185 3,401,282 15,732,794
Louisiana 329,371 930,317 359,032 3,603,150 14,600,927
Maine 106,289 308,112 90,583 689,442 5,266,431
Maryland 156,801 328,935 219,477 1,081,585 7,022,697
Massachusetts 280,117 804,194 319,206 2,389,395 15,548,735
Michigan 327,833 725,159 456,014 2,494,063 15,606,516
Minnesota 98,537 278,693 99,914 941,974 5,489,548
Mississippi 252,852 540,406 292,655 2,225,936 10,740,702
Missouri 353,492 1,072,302 437,990 3,263,920 17,456,452
Montana 38,232 99,061 26,936 267,472 1,579,162
Nebraska 94,634 238,851 91,552 1,003,496 4,399,812
Nevada 45,535 127,665 45,552 325,019 1,833,087
New Hampshire 40,184 143,511 40,200 449,864 2,330,694
New Jersey 385,643 695,640 382,934 2,702,315 13,263,391
New Mexico**
New York 1,904,657 3,429,346 1,293,585 13,896,087 62,062,404
North Carolina 608,135 1,307,947 511,445 4,906,941 23,676,345
North Dakota 24,720 54,569 26,244 198,945 1,087,191
Ohio 656,535 2,154,127 824,394 7,110,698 33,809,751
Oklahoma 154,964 435,049 97,085 1,096,146 6,366,237
Oregon 54,836 187,056 75,117 566,209 4,159,910
Pennsylvania 347,281 934,426 705,002 3,005,516 16,153,609
Rhode Island 60,429 133,178 58,933 404,984 2,374,298
South Carolina 268,346 597,461 324,087 2,350,308 11,783,717
South Dakota 32,478 74,591 29,661 270,458 1,345,582
Tennessee**
Texas 777,489 2,223,580 657,848 10,093,801 35,857,792
Utah 55,947 175,023 47,561 537,159 3,114,227
Vermont 16,037 42,821 14,114 124,262 715,390
Virginia 242,302 519,649 274,114 2,158,209 10,069,179
Washington 196,331 371,824 152,037 1,540,253 9,066,469
West Virginia 163,120 387,534 134,768 1,212,992 6,794,423
Wisconsin 350,271 654,116 386,065 2,344,346 13,322,825
Wyoming 20,734 47,868 15,911 166,177 791,122
*Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-12
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-13
National Pharmaceutical Council Pharmaceutical Benefits 2007
Hormones and
Central Nervous Cardiovascular Anti-Infective Gastrointestinal Synthetic
State System Drugs Drugs Agents Drugs Substitutes
National Total $13,733,672,000 $4,409,779,315 $3,795,913,778 $2,700,933,651 $3,549,133,873
Alabama $214,552,130 $73,802,209 $56,724,127 $42,880,640 $62,577,950
Alaska $51,014,894 $11,684,647 $11,472,017 $12,305,340 $10,512,077
Arizona*
Arkansas $170,203,870 $44,199,827 $40,494,234 $25,043,648 $46,474,770
California $1,577,940,461 $682,118,842 $428,390,448 $403,356,229 $462,655,404
Colorado $134,522,019 $31,069,329 $24,334,273 $15,250,451 $29,352,001
Connecticut $207,432,304 $57,960,246 $38,900,924 $40,001,158 $36,536,080
Delaware $37,017,954 $11,410,832 $18,490,842 $3,949,655 $11,869,250
District of Columbia $31,752,935 $14,786,072 $7,891,417 $3,211,132 $7,918,431
Florida $692,119,817 $297,390,891 $373,470,079 $215,858,221 $219,223,786
Georgia $398,614,954 $126,712,089 $159,154,053 $70,040,037 $128,895,843
Hawaii $44,911,145 $19,251,022 $8,794,470 $3,724,301 $12,795,327
Idaho $71,222,640 $11,532,719 $11,186,208 $8,725,592 $15,618,743
Illinois**
Indiana $323,309,355 $71,032,439 $45,461,298 $43,184,105 $63,929,980
Iowa $198,345,246 $36,978,920 $32,909,189 $21,727,070 $38,930,947
Kansas $139,644,790 $27,725,243 $20,320,128 $26,999,791 $25,896,170
Kentucky $273,903,838 $86,644,725 $68,996,989 $37,610,724 $83,549,039
Louisiana $304,695,909 $104,488,213 $125,903,628 $71,097,667 $88,786,676
Maine $122,675,758 $32,682,598 $19,919,917 $33,336,199 $32,003,288
Maryland $235,878,248 $65,233,868 $44,863,927 $34,062,328 $36,101,160
Massachusetts $438,462,703 $102,324,635 $98,710,494 $79,285,503 $87,437,122
Michigan $465,642,417 $92,298,628 $56,806,194 $62,302,650 $78,582,106
Minnesota $220,614,609 $30,636,546 $24,491,736 $32,874,924 $32,255,840
Mississippi $197,640,832 $95,740,331 $67,825,156 $24,652,569 $65,517,465
Missouri $508,352,069 $140,298,572 $100,989,144 $46,536,754 $122,625,807
Montana $49,313,924 $8,372,267 $6,528,375 $5,224,250 $9,202,773
Nebraska $113,869,878 $24,858,618 $18,368,009 $9,244,009 $24,930,071
Nevada $55,822,280 $13,007,296 $11,236,673 $4,507,500 $10,342,649
New Hampshire $67,832,710 $11,590,852 $6,914,941 $8,439,575 $12,275,482
New Jersey $373,529,060 $150,004,977 $118,893,816 $91,234,292 $89,192,201
New Mexico**
New York $1,552,391,330 $625,561,684 $788,859,153 $361,966,786 $478,979,355
North Carolina $599,486,231 $204,569,508 $152,027,401 $174,448,054 $160,898,618
North Dakota $30,502,365 $5,935,677 $4,170,398 $2,572,846 $5,928,454
Ohio $794,592,304 $206,292,755 $150,805,411 $175,539,234 $188,600,216
Oklahoma $184,266,645 $43,651,603 $45,209,726 $29,227,955 $49,617,242
Oregon $159,525,446 $15,790,550 $9,734,364 $8,507,078 $15,961,846
Pennsylvania $373,905,197 $106,055,869 $57,962,409 $58,189,032 $81,182,254
Rhode Island $74,733,675 $23,064,893 $11,509,528 $15,060,588 $14,161,908
South Carolina $249,532,462 $109,550,871 $76,671,996 $32,671,736 $84,043,918
South Dakota $36,887,007 $6,464,738 $7,362,362 $7,712,871 $8,549,059
Tennessee**
Texas $800,062,681 $262,986,093 $253,264,190 $150,787,827 $248,184,183
Utah $105,497,120 $16,041,107 $15,929,708 $16,032,323 $19,073,269
Vermont $20,138,225 $5,732,917 $4,024,154 $3,872,914 $4,718,765
Virginia $226,513,235 $80,628,883 $43,975,229 $56,436,937 $53,220,641
Washington $293,834,554 $66,578,485 $47,705,204 $48,282,935 $66,030,231
West Virginia $168,731,118 $52,797,324 $33,163,561 $37,055,041 $46,158,335
Wisconsin $319,637,524 $99,102,590 $40,550,320 $42,744,865 $72,772,136
Wyoming $22,596,132 $3,136,315 $4,545,958 $3,158,315 $5,065,005
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-14
National Pharmaceutical Council Pharmaceutical Benefits 2007
Unclassified Blood
Therapeutic Autonomic Formulation and
State Agents Drugs Coagulation Other Totals
National Average $1,531,040,695 $1,596,864,325 $1,998,438,628 $4,775,919,111 $38,091,695,376
Alabama $24,902,512 $26,906,221 $36,933,895 $90,883,496 $630,163,180
Alaska $5,255,423 $5,105,214 $10,059,442 $13,778,167 $131,187,221
Arizona*
Arkansas $18,069,153 $21,417,826 $24,380,875 $54,212,690 $444,496,893
California $192,095,334 $127,816,349 $286,819,093 $429,053,695 $4,590,245,855
Colorado $13,767,441 $15,695,757 $9,426,888 $38,883,092 $312,301,251
Connecticut $17,629,346 $19,935,083 $22,897,258 $53,228,609 $494,521,008
Delaware $5,257,686 $4,200,231 $4,684,696 $15,507,441 $112,388,587
District of Columbia $2,924,181 $2,471,190 $4,860,522 $13,764,239 $89,580,119
Florida $100,347,671 $108,548,324 $147,058,338 $316,945,389 $2,470,962,516
Georgia $44,594,047 $67,576,711 $63,100,564 $190,863,020 $1,249,551,318
Hawaii $7,371,604 $4,498,000 $8,502,032 $14,156,230 $124,004,131
Idaho $6,945,664 $6,164,709 $4,197,023 $16,715,213 $152,308,511
Illinois**
Indiana $32,440,671 $33,643,946 $76,146,048 $98,359,441 $787,507,283
Iowa $15,643,316 $18,894,992 $12,624,738 $46,233,132 $422,287,550
Kansas $11,255,310 $13,421,479 $11,580,473 $31,179,253 $308,022,637
Kentucky $33,464,592 $50,973,672 $39,967,530 $118,371,796 $793,482,905
Louisiana $34,330,832 $50,106,962 $49,998,356 $161,817,388 $991,225,631
Maine $10,869,487 $13,004,310 $11,795,168 $28,510,727 $304,797,452
Maryland $16,551,728 $15,976,236 $30,127,136 $44,818,569 $523,613,200
Massachusetts $34,273,891 $35,801,824 $47,032,500 $105,604,352 $1,028,933,024
Michigan $39,756,274 $36,295,568 $56,333,032 $96,767,421 $984,784,290
Minnesota $15,548,784 $15,764,632 $21,201,894 $45,413,234 $438,802,199
Mississippi $24,256,906 $27,533,003 $36,366,456 $80,103,307 $619,636,025
Missouri $50,091,418 $62,451,303 $64,889,970 $167,455,537 $1,263,690,574
Montana $5,364,423 $5,053,922 $3,495,037 $12,332,512 $104,887,483
Nebraska $11,022,585 $11,866,646 $8,637,603 $30,919,635 $253,717,054
Nevada $5,367,911 $6,383,591 $9,908,700 $15,563,837 $132,140,437
New Hampshire $4,695,907 $6,840,460 $3,739,775 $15,061,722 $137,391,424
New Jersey $46,846,440 $50,599,505 $74,917,112 $155,552,870 $1,150,770,273
New Mexico**
New York $211,252,457 $172,267,631 $254,109,864 $716,433,091 $5,161,821,351
North Carolina $64,885,022 $81,250,090 $82,523,055 $243,656,396 $1,763,744,375
North Dakota $2,794,304 $3,298,133 $2,034,759 $7,731,194 $64,968,130
Ohio $70,270,337 $105,004,513 $72,270,082 $241,525,465 $2,004,900,317
Oklahoma $22,920,597 $23,558,595 $27,967,206 $53,652,385 $480,071,954
Oregon $6,401,798 $8,281,421 $10,262,503 $16,025,750 $250,490,756
Pennsylvania $36,212,113 $57,971,113 $70,200,216 $120,431,391 $962,109,594
Rhode Island $6,370,996 $7,774,511 $6,421,812 $17,693,234 $176,791,145
South Carolina $31,534,376 $33,911,644 $37,270,088 $102,302,056 $757,489,147
South Dakota $3,662,431 $4,733,561 $2,634,571 $11,629,219 $89,635,819
Tennessee**
Texas $119,441,273 $102,902,689 $128,618,140 $413,010,166 $2,479,257,242
Utah $7,407,843 $8,488,557 $3,037,342 $22,148,801 $213,656,070
Vermont $2,362,088 $2,046,736 $1,752,162 $5,865,446 $50,513,407
Virginia $27,376,114 $30,480,949 $36,095,697 $81,306,462 $636,034,147
Washington $29,815,033 $28,202,835 $32,757,379 $73,385,010 $686,591,666
West Virginia $18,706,956 $21,003,967 $12,706,954 $49,301,388 $439,624,644
Wisconsin $36,029,761 $38,366,790 $34,832,125 $90,896,400 $774,932,511
Wyoming $2,656,659 $2,372,924 $1,262,519 $6,869,243 $51,663,070
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-15
National Pharmaceutical Council Pharmaceutical Benefits 2007
Hormones and
Central Nervous Cardiovascular Anti-Infective Gastrointestinal Synthetic
State System Drugs Drugs Agents Drugs Substitutes
National Average 170,427,000 83,641,573 45,217,584 34,767,721 55,118,108
Alabama 3,232,377 1,599,474 1,085,636 644,601 1,122,760
Alaska 610,394 274,332 132,139 126,111 176,203
Arizona*
Arkansas 2,010,056 906,451 797,064 309,713 739,529
California 15,109,303 9,201,039 3,849,081 3,749,245 5,820,996
Colorado 1,951,438 745,356 510,657 273,249 648,137
Connecticut 2,185,526 1,072,706 275,250 415,595 602,431
Delaware 535,501 203,661 174,139 67,245 175,637
District of Columbia 317,407 265,006 59,784 39,592 112,959
Florida 9,722,766 6,174,856 2,848,958 2,205,231 3,383,461
Georgia 5,861,309 2,725,527 2,570,140 1,063,572 2,205,235
Hawaii 497,817 354,399 90,949 148,055 182,372
Idaho 835,517 242,690 217,691 114,922 246,632
Illinois**
Indiana 4,137,565 1,609,777 775,277 928,445 1,085,729
Iowa 2,521,064 894,375 622,769 361,015 699,054
Kansas 1,649,419 629,139 372,469 279,853 496,858
Kentucky 4,528,809 2,032,296 1,355,734 1,065,834 1,394,072
Louisiana 3,983,412 1,923,705 1,710,966 660,789 1,376,986
Maine 2,052,292 816,224 366,491 370,755 612,210
Maryland 2,754,822 1,343,091 338,537 390,093 700,452
Massachusetts 5,765,456 2,489,395 959,958 963,925 1,602,847
Michigan 6,457,330 2,448,637 834,280 930,390 1,452,311
Minnesota 2,257,637 666,445 326,779 484,725 536,286
Mississippi 2,635,134 1,807,777 1,053,455 439,131 1,025,501
Missouri 6,139,842 2,883,016 1,306,399 1,065,719 1,931,857
Montana 591,123 187,570 125,063 99,015 175,685
Nebraska 1,434,507 518,840 397,467 345,237 421,290
Nevada 639,293 287,520 124,591 92,333 182,254
New Hampshire 908,891 263,570 150,385 175,071 214,359
New Jersey 4,090,116 2,590,500 754,730 906,408 1,326,516
New Mexico**
New York 17,070,337 10,354,197 5,146,710 4,479,018 6,335,159
North Carolina 7,141,343 3,954,735 2,052,837 1,533,553 2,577,796
North Dakota 380,673 158,590 92,834 53,868 121,278
Ohio 11,170,571 4,583,729 2,384,308 2,641,502 3,226,628
Oklahoma 2,309,383 819,705 845,779 388,735 715,057
Oregon 1,933,176 415,564 183,974 225,094 325,629
Pennsylvania 4,714,134 2,338,546 894,317 991,202 1,494,551
Rhode Island 891,322 368,066 117,465 179,032 208,483
South Carolina 3,187,298 2,220,303 1,005,899 514,780 1,410,470
South Dakota 428,323 162,233 156,281 79,726 149,127
Tennessee**
Texas 9,880,766 3,466,170 4,998,083 1,758,482 2,951,423
Utah 1,343,038 320,991 335,403 201,063 346,332
Vermont 255,142 110,272 54,629 47,901 73,472
Virginia 3,085,474 1,598,875 604,891 826,757 946,086
Washington 4,180,750 1,740,708 700,145 923,497 1,269,554
West Virginia 2,539,372 1,051,990 657,038 432,186 754,162
Wisconsin 4,231,728 2,748,853 701,823 729,301 1,483,433
Wyoming 268,047 70,672 98,330 46,155 78,849
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-16
National Pharmaceutical Council Pharmaceutical Benefits 2007
Unclassified Blood
Therapeutic Autonomic Formulation and
State Agents Drugs Coagulation Other Totals
National Average 13,872,440 31,707,457 13,668,638 110,492,191 558,912,712
Alabama 249,974 694,644 247,378 2,589,866 11,466,710
Alaska 44,674 102,589 37,678 277,212 1,781,332
Arizona*
Arkansas 163,863 367,964 131,600 1,290,170 6,716,410
California 1,481,054 2,462,289 1,580,317 8,783,238 52,036,562
Colorado 133,969 369,963 120,668 983,483 5,736,920
Connecticut 169,312 323,166 182,273 1,025,352 6,251,611
Delaware 44,977 110,129 30,635 334,680 1,676,604
District of Columbia 28,904 53,811 29,464 248,686 1,155,613
Florida 977,582 2,013,218 1,031,348 6,455,672 34,813,092
Georgia 422,757 1,451,034 489,590 4,881,777 21,670,941
Hawaii 78,672 84,267 49,640 335,040 1,821,211
Idaho 59,982 134,853 43,874 380,176 2,276,337
Illinois**
Indiana 246,947 681,706 333,228 2,490,801 12,289,475
Iowa 148,981 392,669 155,720 1,222,532 7,018,179
Kansas 108,372 261,488 100,219 827,685 4,725,502
Kentucky 353,525 983,113 380,345 3,448,554 15,542,282
Louisiana 339,626 996,979 355,880 3,604,383 14,952,726
Maine 109,353 326,020 98,520 723,994 5,475,859
Maryland 181,817 361,515 231,784 1,131,438 7,433,549
Massachusetts 305,702 805,523 322,087 2,384,308 15,599,201
Michigan 362,779 785,156 467,378 2,580,723 16,318,984
Minnesota 107,496 293,020 103,820 987,480 5,763,688
Mississippi 236,774 502,867 272,941 2,015,122 9,988,702
Missouri 415,649 1,165,688 485,404 3,530,175 18,923,749
Montana 41,823 100,203 27,046 272,478 1,620,006
Nebraska 105,789 249,910 96,657 1,056,357 4,626,054
Nevada 49,906 131,855 51,137 330,829 1,889,718
New Hampshire 43,174 133,998 44,477 436,470 2,370,395
New Jersey 442,378 755,398 387,161 2,886,268 14,139,475
New Mexico**
New York 1,947,303 3,592,303 1,119,760 13,203,806 63,248,593
North Carolina 634,829 1,418,575 525,697 5,156,017 24,995,382
North Dakota 26,449 58,191 26,508 201,365 1,119,756
Ohio 728,016 2,253,944 864,499 7,110,606 34,963,803
Oklahoma 201,845 488,102 107,014 1,211,519 7,087,139
Oregon 55,744 168,024 71,831 536,571 3,915,607
Pennsylvania 346,344 874,882 665,002 2,770,224 15,089,202
Rhode Island 68,114 136,714 69,663 414,330 2,453,189
South Carolina 264,171 627,410 325,835 2,358,438 11,914,604
South Dakota 36,195 78,939 30,019 278,381 1,399,224
Tennessee**
Texas 893,880 2,327,948 813,612 10,860,530 37,950,894
Utah 65,825 195,210 49,106 587,937 3,444,905
Vermont 17,037 42,698 15,392 122,725 739,268
Virginia 276,240 538,056 267,360 2,173,778 10,317,517
Washington 248,490 632,589 258,590 2,120,753 12,075,076
West Virginia 193,375 437,372 149,244 1,306,689 7,521,428
Wisconsin 391,320 691,822 405,454 2,396,776 13,780,510
Wyoming 21,452 49,643 15,783 166,797 815,728
*Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-17
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-18
National Pharmaceutical Council Pharmaceutical Benefits 2007
Hormones and
Central Nervous Cardiovascular Anti-Infective Gastrointestinal Synthetic
State System Drugs Drugs Agents Drugs Substitutes
National Total $7,700,546,892 $1,542,565,701 $2,595,119,847 $1,213,134,157 $2,010,561,660
Alabama $143,746,263 $29,984,767 $46,662,490 $21,266,913 $43,033,435
Alaska $33,241,269 $4,611,581 $9,106,509 $6,283,982 $5,911,697
Arizona*
Arkansas $120,775,180 $14,558,092 $36,126,566 $17,801,495 $32,430,203
California $916,478,860 $224,184,513 $241,260,807 $164,265,390 $268,043,142
Colorado $80,174,650 $10,640,557 $17,869,192 $8,254,254 $17,480,342
Connecticut $74,852,777 $14,141,558 $20,075,685 $12,409,803 $12,872,634
Delaware $32,178,552 $7,543,843 $14,746,762 $5,365,936 $10,516,995
District of Columbia $25,548,587 $7,427,462 $4,988,651 $2,203,638 $4,989,320
Florida $314,145,818 $75,521,349 $201,686,102 $80,376,193 $99,887,497
Georgia $234,302,560 $51,013,715 $103,749,889 $36,274,747 $72,037,944
Hawaii $23,127,594 $4,865,756 $4,683,872 $2,268,440 $4,455,398
Idaho $47,744,673 $4,337,593 $8,337,967 $5,220,520 $9,941,860
Illinois**
Indiana $119,928,901 $20,040,525 $16,200,880 $16,697,798 $21,212,940
Iowa $114,434,163 $12,557,860 $24,632,339 $11,402,849 $22,151,730
Kansas $75,217,177 $8,386,720 $12,156,381 $11,160,841 $12,551,899
Kentucky $164,544,818 $42,190,381 $52,291,447 $22,139,298 $52,842,763
Louisiana $191,578,852 $42,378,843 $108,767,280 $38,712,365 $58,147,923
Maine $70,513,562 $12,885,929 $13,490,132 $16,817,459 $19,500,312
Maryland $142,829,425 $11,374,011 $24,409,946 $7,410,054 $10,715,505
Massachusetts $206,084,564 $33,334,340 $59,973,952 $21,136,913 $42,721,614
Michigan $247,854,895 $10,371,673 $35,087,371 $15,017,919 $26,345,293
Minnesota $105,365,936 $12,443,620 $15,635,016 $16,383,207 $18,531,175
Mississippi $86,969,491 $19,889,378 $44,854,273 $9,341,908 $27,944,889
Missouri $249,014,975 $47,194,066 $55,666,945 $20,952,104 $58,798,320
Montana $29,830,562 $2,837,818 $4,323,700 $2,683,522 $4,634,992
Nebraska $66,174,725 $7,159,551 $13,216,063 $6,365,731 $13,534,467
Nevada $37,531,155 $4,881,067 $8,565,274 $2,881,887 $6,011,462
New Hampshire $33,169,018 $3,899,765 $4,646,416 $3,966,267 $7,339,516
New Jersey $176,610,382 $42,896,940 $71,187,349 $32,240,506 $38,578,589
New Mexico**
New York $998,122,069 $291,182,550 $648,616,265 $142,047,799 $339,493,318
North Carolina $335,821,426 $63,780,863 $109,302,988 $79,259,159 $90,679,910
North Dakota $14,465,289 $1,408,343 $2,766,567 $1,099,853 $2,681,601
Ohio $448,392,643 $90,909,082 $87,780,976 $114,665,119 $105,983,118
Oklahoma $109,447,270 $13,693,120 $34,117,111 $17,149,198 $32,566,766
Oregon $88,803,635 $4,616,121 $4,863,296 $3,940,110 $7,388,078
Pennsylvania $169,093,547 $33,747,110 $33,888,739 $17,938,067 $39,236,433
Rhode Island $32,360,407 $6,887,360 $6,006,430 $5,967,807 $5,478,297
South Carolina $136,947,640 $28,725,321 $50,035,501 $16,902,273 $44,715,335
South Dakota $20,067,869 $1,665,243 $5,674,689 $3,052,793 $5,086,563
Tennessee**
Texas $561,737,141 $88,326,294 $221,818,603 $78,950,703 $166,489,536
Utah $64,828,269 $6,459,755 $11,025,175 $8,676,963 $11,575,737
Vermont $12,464,283 $1,869,488 $2,991,551 $1,376,888 $2,726,718
Virginia $100,982,471 $16,673,791 $22,178,943 $20,699,036 $20,603,187
Washington $166,564,339 $28,117,648 $26,671,731 $26,572,238 $39,009,489
West Virginia $126,890,388 $29,233,450 $26,190,868 $28,581,250 $31,999,775
Wisconsin $134,454,261 $50,496,502 $22,702,578 $26,968,386 $38,273,699
Wyoming $15,134,561 $1,220,387 $4,088,580 $1,984,576 $3,410,244
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-19
National Pharmaceutical Council Pharmaceutical Benefits 2007
Unclassified Blood
Therapeutic Autonomic Formulation and
State Agents Drugs Coagulation Other Totals
National Average $818,108,654 $744,328,825 $1,198,511,289 $2,853,858,420 $20,676,735,445
Alabama $19,499,211 $14,020,830 $24,879,590 $64,838,385 $407,931,884
Alaska $2,833,646 $2,724,173 $4,641,142 $8,403,128 $77,757,127
Arizona*
Arkansas $14,630,219 $9,786,634 $14,823,473 $39,726,486 $300,658,348
California $82,902,027 $57,519,946 $214,364,933 $233,135,375 $2,402,154,993
Colorado $7,017,156 $6,930,067 $6,937,339 $21,303,692 $176,607,249
Connecticut $5,152,854 $5,172,366 $10,360,664 $22,154,497 $177,192,838
Delaware $4,562,247 $3,003,717 $2,745,930 $11,854,076 $92,518,058
District of Columbia $1,594,547 $1,748,463 $3,065,731 $9,053,604 $60,620,003
Florida $45,069,196 $42,953,771 $108,702,993 $144,256,944 $1,112,599,863
Georgia $25,326,476 $32,207,168 $36,526,355 $114,072,252 $705,511,106
Hawaii $1,825,446 $1,580,528 $5,982,712 $7,961,557 $56,751,303
Idaho $4,431,676 $3,146,359 $3,448,561 $10,819,832 $97,429,041
Illinois**
Indiana $13,362,647 $9,532,772 $41,859,401 $52,670,361 $311,506,225
Iowa $9,032,101 $9,858,695 $8,347,641 $25,178,243 $237,595,621
Kansas $5,760,622 $5,070,803 $7,947,380 $15,829,567 $154,081,390
Kentucky $20,607,958 $25,954,477 $20,936,142 $76,672,179 $478,179,463
Louisiana $24,255,850 $31,645,989 $30,710,516 $108,336,504 $634,534,122
Maine $5,363,342 $7,564,323 $7,050,279 $16,829,459 $170,014,797
Maryland $4,130,464 $3,515,563 $14,958,326 $12,868,548 $232,211,842
Massachusetts $15,608,493 $12,192,897 $32,019,478 $54,615,766 $477,688,017
Michigan $12,746,756 $7,425,208 $26,752,683 $37,871,620 $419,473,418
Minnesota $8,128,640 $6,806,297 $11,543,947 $27,905,968 $222,743,806
Mississippi $11,501,217 $8,942,660 $18,410,348 $38,724,260 $266,578,424
Missouri $25,134,460 $24,523,450 $34,762,130 $90,597,900 $606,644,350
Montana $2,713,509 $2,296,988 $2,949,472 $6,367,975 $58,638,538
Nebraska $6,162,850 $6,143,913 $6,744,105 $18,490,678 $143,992,083
Nevada $2,985,989 $3,311,541 $5,099,908 $8,817,362 $80,085,645
New Hampshire $2,654,103 $2,696,695 $1,492,142 $7,644,890 $67,508,812
New Jersey $17,350,933 $17,579,775 $29,720,047 $63,453,188 $489,617,709
New Mexico**
New York $124,570,887 $113,576,351 $140,008,671 $486,869,777 $3,284,487,687
North Carolina $38,849,460 $40,131,764 $47,427,452 $153,085,320 $958,338,342
North Dakota $1,262,635 $1,282,869 $1,165,327 $3,848,021 $29,980,505
Ohio $40,677,917 $45,783,580 $38,807,475 $149,124,532 $1,122,124,442
Oklahoma $17,499,026 $13,897,068 $28,462,775 $48,204,260 $315,036,594
Oregon $2,562,224 $3,050,596 $7,180,358 $7,300,034 $129,704,452
Pennsylvania $17,648,555 $17,721,188 $33,582,881 $55,474,673 $418,331,193
Rhode Island $2,190,159 $2,207,954 $3,161,071 $7,312,534 $71,572,019
South Carolina $16,739,759 $16,672,622 $18,679,468 $69,615,830 $399,033,749
South Dakota $2,208,896 $2,133,782 $779,128 $6,082,650 $46,751,613
Tennessee**
Texas $86,087,871 $62,285,205 $73,151,821 $336,580,952 $1,675,428,126
Utah $4,260,105 $4,615,122 $1,259,995 $13,798,586 $126,499,707
Vermont $1,088,566 $875,545 $813,502 $3,574,351 $27,780,892
Virginia $11,094,798 $10,906,018 $13,042,209 $34,907,023 $251,087,476
Washington $14,420,598 $14,078,152 $27,522,310 $39,254,040 $382,210,545
West Virginia $13,923,110 $12,162,474 $6,543,816 $35,977,765 $311,502,896
Wisconsin $18,905,113 $15,882,983 $18,325,654 $47,972,830 $373,982,006
Wyoming $1,774,340 $1,209,484 $814,008 $4,420,946 $34,057,126
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-20
National Pharmaceutical Council Pharmaceutical Benefits 2007
Hormones and
Central Nervous Cardiovascular Anti-Infective Gastrointestinal Synthetic
State System Drugs Drugs Agents Drugs Substitutes
National Average 101,452,174 28,203,842 30,878,339 17,766,354 26,670,619
Alabama 2,140,899 626,089 875,200 306,598 639,857
Alaska 400,715 101,198 100,459 60,469 86,118
Arizona*
Arkansas 1,407,588 296,563 715,074 169,241 455,748
California 9,045,439 2,802,484 2,272,797 1,780,218 2,987,599
Colorado 1,069,789 226,303 348,885 113,335 296,045
Connecticut 842,376 248,753 99,701 150,737 172,392
Delaware 474,668 130,858 156,811 59,810 146,347
District of Columbia 249,844 126,349 41,333 23,539 62,707
Florida 4,682,035 1,496,059 1,687,208 736,934 1,247,809
Georgia 3,325,834 1,005,160 1,505,795 477,122 1,072,908
Hawaii 291,116 89,187 40,895 104,963 59,613
Idaho 584,587 91,635 185,790 60,558 139,064
Illinois**
Indiana 1,738,698 418,362 243,969 474,287 310,445
Iowa 1,565,908 286,447 465,216 174,881 337,777
Kansas 875,285 180,285 226,501 103,177 194,544
Kentucky 3,114,057 925,591 1,045,996 717,153 778,443
Louisiana 2,572,304 746,509 1,427,240 324,959 811,707
Maine 1,195,715 287,935 265,162 168,878 328,132
Maryland 1,504,685 238,501 124,899 81,527 177,577
Massachusetts 3,216,404 867,308 583,917 439,162 731,786
Michigan 3,681,581 263,324 419,125 289,437 335,703
Minnesota 1,214,947 247,991 197,012 306,870 240,828
Mississippi 1,227,077 398,210 756,906 138,912 401,681
Missouri 3,293,133 922,232 763,857 523,803 819,297
Montana 356,695 61,087 85,760 55,737 76,651
Nebraska 868,548 143,502 297,662 250,327 189,594
Nevada 414,998 105,097 83,276 46,699 86,000
New Hampshire 504,913 84,574 106,934 93,683 99,823
New Jersey 1,809,268 722,488 350,018 286,848 468,141
New Mexico**
New York 11,966,230 4,698,451 4,045,185 3,073,156 3,954,280
North Carolina 4,261,361 1,174,949 1,581,818 658,914 1,238,184
North Dakota 204,089 35,843 62,089 17,811 46,265
Ohio 6,478,642 1,857,167 1,398,871 1,495,818 1,536,416
Oklahoma 1,468,699 256,625 661,126 180,832 400,746
Oregon 1,114,049 100,201 93,804 152,376 118,415
Pennsylvania 3,120,422 989,450 604,944 515,994 742,156
Rhode Island 444,880 98,040 51,035 79,066 70,050
South Carolina 1,819,565 555,888 726,125 229,727 656,080
South Dakota 242,537 39,570 120,351 33,928 67,594
Tennessee**
Texas 7,148,798 1,140,878 4,049,974 969,390 1,671,886
Utah 873,697 126,180 247,456 115,845 187,596
Vermont 179,815 34,077 41,798 21,819 38,697
Virginia 1,603,379 316,100 310,353 433,665 307,837
Washington 2,600,102 683,471 408,939 621,500 645,765
West Virginia 1,971,453 567,686 537,186 282,285 485,447
Wisconsin 2,106,763 1,363,795 384,407 339,608 704,710
Wyoming 178,587 25,390 79,480 24,756 44,159
* Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-21
National Pharmaceutical Council Pharmaceutical Benefits 2007
Unclassified Blood
Therapeutic Autonomic Formulation and
State Agents Drugs Coagulation Other Totals
National Average 6,268,434 17,537,906 4,891,738 63,907,736 297,577,142
Alabama 168,748 454,060 88,786 1,660,430 6,960,667
Alaska 20,134 62,007 10,788 156,362 998,250
Arizona*
Arkansas 115,553 239,732 31,557 852,224 4,283,280
California 490,423 1,331,965 940,240 5,341,431 26,992,596
Colorado 53,060 198,805 28,935 476,276 2,811,433
Connecticut 35,658 111,426 41,682 367,873 2,070,598
Delaware 34,489 90,999 14,446 258,039 1,366,467
District of Columbia 11,727 37,341 15,756 148,948 717,544
Florida 353,914 942,475 276,286 2,666,541 14,089,261
Georgia 201,071 762,350 180,934 2,630,570 11,161,744
Hawaii 17,075 39,586 18,354 187,607 848,396
Idaho 32,321 86,270 15,178 241,371 1,436,774
Illinois**
Indiana 60,883 224,143 109,361 1,051,010 4,631,158
Iowa 74,570 222,141 47,273 687,138 3,861,351
Kansas 44,893 117,478 23,634 375,721 2,141,518
Kentucky 193,352 607,576 148,184 2,304,238 9,834,590
Louisiana 206,173 675,836 128,269 2,360,905 9,253,902
Maine 46,200 182,939 26,170 360,048 2,861,179
Maryland 29,873 111,830 57,114 292,043 2,618,049
Massachusetts 125,210 383,543 87,330 1,213,739 7,648,399
Michigan 78,102 230,965 109,658 877,786 6,285,681
Minnesota 44,793 147,473 37,259 591,387 3,028,560
Mississippi 100,173 252,461 58,145 1,051,456 4,385,021
Missouri 180,439 558,733 186,344 1,793,995 9,041,833
Montana 18,383 54,971 6,505 130,934 846,723
Nebraska 52,845 145,155 28,543 705,180 2,681,356
Nevada 21,349 76,150 17,695 169,091 1,020,355
New Hampshire 19,261 67,274 12,445 217,324 1,206,231
New Jersey 131,048 299,878 102,911 1,190,262 5,360,862
New Mexico**
New York 991,934 2,542,133 405,051 8,927,090 40,603,510
North Carolina 314,040 827,444 157,782 3,036,909 13,251,401
North Dakota 8,953 28,863 5,480 77,492 486,885
Ohio 345,995 1,153,570 340,786 3,837,740 18,445,005
Oklahoma 138,427 323,674 34,860 708,101 4,173,090
Oregon 17,057 76,252 17,161 285,319 1,974,634
Pennsylvania 159,531 409,135 242,006 1,438,404 8,222,042
Rhode Island 20,348 51,280 21,006 188,706 1,024,411
South Carolina 113,591 357,987 104,118 1,409,132 5,972,213
South Dakota 18,183 43,981 5,486 135,529 707,159
Tennessee**
Texas 611,094 1,640,532 271,786 8,561,048 26,065,386
Utah 30,652 116,790 18,019 365,710 2,081,945
Vermont 7,224 22,715 4,337 73,197 423,679
Virginia 90,846 223,178 82,272 1,109,731 4,477,361
Washington 97,358 359,914 87,068 1,249,585 6,753,702
West Virginia 132,063 314,339 70,166 897,331 5,257,956
Wisconsin 196,115 297,400 170,233 1,146,725 6,709,756
Wyoming 13,303 33,157 4,339 100,058 503,229
*Data not reported for Arizona. Arizona has a 1115 waiver for which special rules apply.
** Data not reported for Illinois, New Mexico and Tennessee due to inconsistencies.
4-22
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-23
National Pharmaceutical Council Pharmaceutical Benefits 2007
In 1990, Congress considered a number of proposals designed to reduce and control Federal and State
expenditures for prescription drug products provided to Medicaid patients (S.2605, the
Pharmaceutical Access and Prudent Purchasing Act; S.3029, the Medicaid Anti-Discriminatory Drug
Act, sponsored by Senator David Pryor; and H.R.5589, the Medicaid Prescription Drug Fair Access
and Pricing Act, sponsored by Representatives Ron Wyden and Jim Cooper). A vigorous
Congressional debate ensued over which of these approaches to pursue. Several pharmaceutical
manufacturers voluntarily offered rebates to the States in exchange for open access for their products,
while the Pharmaceutical Manufacturers Association proposed a set rebate amount in exchange for
open formularies. Numerous public interest groups offered opinions on the proposals and in some
cases proposals of their own.
The Congressional debate ended in both the House and Senate offering somewhat similar proposals.
During the ensuing Conference between the House and Senate, the Office of Management and Budget
(OMB) argued for the inclusion of several proposals into the provisions in budget bill, the Omnibus
Budget Reconciliation Act of 1990 (OBRA ’90). The resulting Public Law 101-508, enacted
November 5, 1990, required a drug manufacturer to enter into and have in effect a national rebate
agreement with the Secretary of DHHS for States to receive Federal funding for outpatient drugs
dispensed to Medicaid patients. (For a detailed account of the debate and genesis of various
provisions see Robert Betz’s analysis of the Medicaid Best Price Law and its effect on pharmaceutical
manufacturers’ pricing policies.")
The requirement for rebate agreements does not apply to the dispensing of a single-source or
innovator multiple-source drug if the State has determined that the drug is essential, rated 1-A by the
FDA, and prior authorization is obtained for the exception. Existing rebate agreements qualify under
the law if the State agrees to report all rebates to DHHS and the agreement provides for a minimum
aggregate rebate of 10% of the State’s expenditures for the manufacturer’s products.
OBRA ‘90 was amended by the Veterans Health Care Act of 1992 which also required a drug
manufacturer to enter into discount pricing agreements with the Department of Veterans Affairs and
with covered entities funded by the Public Health Service in order to have its drugs covered by
Medicaid. The Medicaid rebate law, as amended, is included as Appendix C.
The drug rebate program is administered by CMS’ Center for Medicaid and State Operations
(CMSO). Currently, the rebate for covered outpatient drugs is as follows:
! For all innovator products, reimbursement requires: (1) a rebate that is the greater of 15.1
percent of the average manufacturer’s price (AMP) or the difference between the AMP and
the manufacturer’s “best price,” and (2) an additional rebate for any price increase for a
product that exceeds the increase in the Consumer Price Index (CPI-U) for all items since the
fall of 1990. AMP is the average price paid by wholesalers for products distributed to the
retail class of trade. The best price is the lowest price offered to any other customer,
excluding Federal Supply Schedule prices, prices to State pharmaceutical assistance
programs, and prices that are nominal in amount, and includes all discounts and rebates.
! For generic drugs (non-innovator drugs), reimbursement requires: a rebate of 11 percent of
each product’s AMP.
"
Robert Betz, “The Medicaid Best Price Law and Its Effect on Pharmaceutical Manufacturer’s Pricing Policies and Behavior for
Name Brand, Outpatient Pharmaceutical Products,” unpubl. Ph.D. dissertation, The George Washington University, May 21,
2000.
4-24
National Pharmaceutical Council Pharmaceutical Benefits 2007
Allocation of
State Drug Rebate Monies1 Total Rebates2 Federal Share2
National Total $12,409,442,413 $7,171,923,418
Alabama Medicaid General $145,238,083 $103,232,896
Alaska Medicaid General $27,511,193 $15,840,945
Arizona* - - -
Arkansas Medicaid Drug Budget $93,635,941 $70,052,049
California Medicaid Drug Budget $2,056,515,858 $1,055,322,930
Colorado Medicaid General $74,633,154 $37,746,924
Connecticut General Fund $109,418,487 $54,760,945
Delaware Medicaid General $35,424,633 $18,108,454
District of Columbia General Fund $24,703,979 $17,293,632
Florida Medicaid Drug Budget $728,568,990 $429,549,051
Georgia Medicaid General $336,290,253 $204,764,236
Hawaii General Fund $25,103,501 $14,678,017
Idaho Medicaid General $48,525,397 $34,268,635
Illinois Medicaid Drug Budget $575,457,731 $289,935,647
Indiana General Fund $204,350,287 $128,403,306
Iowa Medicaid Drug Budget $90,050,305 $57,237,973
Kansas Medicaid Drug Budget $93,125,615 $56,998,633
Kentucky General Fund $217,275,788 $151,461,068
Louisiana Medicaid Drug Budget $278,830,912 $198,561,571
Maine General Fund $99,804,572 $64,958,802
Maryland Medicaid Drug Budget $154,069,573 $77,297,337
Massachusetts General Fund $281,523,695 $140,761,848
Michigan Medicaid Drug Budget $325,135,732 $184,773,823
Minnesota General Fund $118,040,245 $59,142,717
Mississippi General Fund $180,055,329 $138,986,927
Missouri Medicaid Drug Budget $300,271,256 $184,397,584
Montana Medicaid General $25,166,744 $18,138,955
Nebraska Medicaid General $68,431,450 $41,009,525
Nevada General Fund $34,103,702 $19,100,049
New Hampshire General Fund $37,566,506 $18,924,184
New Jersey Medicaid Drug Budget $261,578,682 $131,087,744
New Mexico Medicaid General $25,417,996 $18,885,572
New York General Fund $1,300,131,531 $650,065,766
North Carolina Medicaid General $452,693,066 $288,839,970
North Dakota Medicaid Drug Budget $15,334,927 $10,380,570
Ohio Medicaid General $591,916,354 $353,797,769
Oklahoma Medicaid General $103,412,619 $72,740,150
Oregon General Fund $60,464,711 $37,234,839
Pennsylvania Medicaid General $253,722,496 $137,457,156
Rhode Island General Fund $44,671,288 $24,738,960
South Carolina Medicaid Drug Budget $217,001,438 $152,540,481
South Dakota Medicaid Drug Budget $22,083,160 $14,646,662
Tennessee Medicaid General $768,857,139 $498,296,312
Texas Medicaid Drug Budget $736,763,024 $449,541,903
Utah General Fund $39,887,001 $28,627,828
Vermont Health Access Trust Fund $45,054,392 $27,124,381
Virginia Virginia Health Care Fund $174,023,976 $87,234,401
Washington General Fund $176,803,507 $89,333,600
West Virginia Medicaid General $114,327,436 $85,345,432
Wisconsin Medicaid General $202,803,404 $120,383,018
Wyoming Medicaid Drug Budget $13,665,355 $7,912,241
*Does not apply for Arizona. Arizona has a 1115 waiver for which special rules apply.
Sources: 1As reported by State drug program administrators in the 2007 NPC Survey; 2 CMS, CMS-64 Report, FY 2005.
Includes reported state supplemental rebates for AL, CA, FL, GA, HI, IA, ID, IL, KS, KY, LA, ME, MI, MN, NH, NV, OH,
TN, VA, VT, WA, and WV.
4-25
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Does not apply for Arizona. Arizona has a 1115 waiver for which special rules apply.
**Includes reported state supplemental rebates.
Source: CMS, CMS-64 Report, FY 2001 - FY 2005.
4-26
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-27
National Pharmaceutical Council Pharmaceutical Benefits 2007
Rebates as % Drug
State Drug Expenditures Rebates** Expenditure
National Total $43,077,457,835 $12,409,442,413 28.8%
Alabama $606,578,572 $145,238,083 23.9%
Alaska $127,315,710 $27,511,193 21.6%
Arizona* $5,486,350 - -
Arkansas $419,350,865 $93,635,941 22.3%
California $5,187,275,034 $2,056,515,858 39.6%
Colorado $285,371,981 $74,633,154 26.2%
Connecticut $496,715,211 $109,418,487 22.0%
Delaware $122,026,857 $35,424,633 29.0%
District of Columbia $105,948,589 $24,703,979 23.3%
Florida $2,503,151,114 $728,568,990 29.1%
Georgia $1,184,915,057 $336,290,253 28.4%
Hawaii $119,852,050 $25,103,501 20.9%
Idaho $168,780,832 $48,525,397 28.8%
Illinois $1,716,361,486 $575,457,731 33.5%
Indiana $751,525,376 $204,350,287 27.2%
Iowa $412,274,229 $90,050,305 21.8%
Kansas $296,283,292 $93,125,615 31.4%
Kentucky $794,519,116 $217,275,788 27.3%
Louisiana $1,082,597,269 $278,830,912 25.8%
Maine $282,039,741 $99,804,572 35.4%
Maryland $578,238,275 $154,069,573 26.6%
Massachusetts $1,067,378,270 $281,523,695 26.4%
Michigan $965,368,582 $325,135,732 33.7%
Minnesota $441,908,835 $118,040,245 26.7%
Mississippi $665,504,688 $180,055,329 27.1%
Missouri $1,246,144,317 $300,271,256 24.1%
Montana $105,154,540 $25,166,744 23.9%
Nebraska $228,576,569 $68,431,450 29.9%
Nevada $134,564,289 $34,103,702 25.3%
New Hampshire $133,253,555 $37,566,506 28.2%
New Jersey $1,158,553,486 $261,578,682 22.6%
New Mexico $116,252,520 $25,417,996 21.9%
New York $5,253,655,620 $1,300,131,531 24.7%
North Carolina $1,790,399,967 $452,693,066 25.3%
North Dakota $64,157,312 $15,334,927 23.9%
Ohio $1,981,230,721 $591,916,354 29.9%
Oklahoma $500,420,840 $103,412,619 20.7%
Oregon $261,373,083 $60,464,711 23.1%
Pennsylvania $1,009,804,038 $253,722,496 25.1%
Rhode Island $173,884,102 $44,671,288 25.7%
South Carolina $716,694,085 $217,001,438 30.3%
South Dakota $88,963,445 $22,083,160 24.8%
Tennessee $2,344,351,015 $768,857,139 32.8%
Texas $2,416,879,360 $736,763,024 30.5%
Utah $221,854,365 $39,887,001 18.0%
Vermont $184,730,219 $45,054,392 24.4%
Virginia $634,701,038 $174,023,976 27.4%
Washington $682,553,233 $176,803,507 25.9%
West Virginia $431,614,161 $114,327,436 26.5%
Wisconsin $759,682,514 $202,803,404 26.7%
Wyoming $51,242,060 $13,665,355 26.7%
*Does not apply to Arizona. Arizona has a 1115 waiver for which special rules apply.
**Includes reported State supplemental rebates.
Source: CMS, CMS-64 Report, FY 2005.
4-28
National Pharmaceutical Council Pharmaceutical Benefits 2007
In general, all prescription products sold by a manufacturer that has signed a drug rebate agreement
are covered outpatient drugs reimbursable by Medicaid. A State Medicaid program may require prior
approval before dispensing of any drug product and may design and implement a formulary intended
to limit coverage for specific drugs. Drug formularies and prior authorization programs must meet
specific requirements established in Medicaid law.
A State Medicaid program can restrict coverage for a drug product through a formulary, if based on
official labeling or information in designated official medical compendia, “the excluded drug does not
have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness or
clinical outcome of such treatment” over other drug products, and there is a written explanation
(available to the public) of the basis for the exclusion. However, drug products excluded from the
formulary under these conditions, nevertheless, must be available through prior authorization.
Drugs in certain specific classes may be restricted or excluded from coverage without regard to the
formulary conditions and need not be available through prior authorization. These classes include:
! Drugs used for anorexia, weight gain, fertility, hair growth, cosmetic effect, symptomatic
relief of cough or colds, or for cessation of smoking.
! Vitamins and minerals (except prenatal prescription vitamins and fluoride preparations) or
non-prescription drugs.
! Drugs that require tests or monitoring services to be purchased exclusively from the
manufacturer or his designee.
! Barbiturates or benzodiazepines.
PRIOR AUTHORIZATION
Whether or not a drug product is on a formulary, States may require physicians to request and receive
official permission before a particular product can be dispensed. This procedure is called Prior
Authorization or Prior Approval.
States may not operate prior authorization plans unless the State provides for a response within 24
hours of a request and provides for a 72-hour emergency supply of the medication.
The Congressional intent for the prior authorization provision was not to encourage the use of such
programs, but rather to make them available to the States for the purpose of controlling utilization of
products that have very narrow indications or high abuse potential.
The majority of States report the establishment of prior authorization programs and have plans to
apply prior authorization to a select number of drugs. Some States will do so only after their Drug
Utilization Review (DUR) program has identified areas of therapeutic concern.
DUR Program. Each State must establish a Drug Utilization Review (DUR) Program in order to
assure that prescriptions are appropriate, medically necessary, and not likely to result in adverse
medical results. A DUR Program consists of prospective and retrospective components as well as
components to educate physicians and pharmacists on common drug therapy problems.
4-29
National Pharmaceutical Council Pharmaceutical Benefits 2007
Specifically, the program educates physicians and pharmacists how to identify and reduce fraud,
abuse, gross overuse, or inappropriate or medically unnecessary care; potential and actual severe
adverse reactions to drugs, including education on therapeutic appropriateness, overutilization and
underutilization, appropriate use of generic products, therapeutic duplication, drug-disease
contraindications, drug-drug interactions, incorrect drug dosage or duration of drug treatment, drug-
allergy interactions, and clinical abuse or misuse.
The two primary objectives of DUR systems are (1) to improve quality of care; and (2) to assist in
containing health care costs. While there is a general belief that DUR is cost beneficial, it is difficult
to isolate concrete evidence that supports this view. The primary issue facing Medicaid DUR
programs is whether or not the systems currently in place (or envisioned) meet the two objectives
outlined above.
Prospective DUR. Prospective DUR is to be conducted at the point of sale (POS) before delivery of a
medication by the pharmacist to the Medicaid recipient or caregiver. The State is to establish
standards for counseling patients and will require the pharmacist to offer to discuss matters, which, in
the exercise of the pharmacist’s professional judgment are deemed significant, including the
following:
! Name, address, telephone number, date of birth (or age) and gender;
! Individual history where significant, including a disease state or states, known allergies and
drug reactions, and a comprehensive list of medications and relevant devices; and
! Pharmacist comments relevant to the individual’s pharmaceutical therapy.
Retrospective DUR. This activity continuously assesses data on drug use against established
standards, preferably using automated claims processing and information retrieval techniques to
monitor for therapeutic appropriateness, overutilization and underutilization, appropriate use of
generic products, therapeutic duplication, drug-disease contraindications, drug-drug interactions,
incorrect drug dosage or duration of drug treatment, clinical abuse/misuse and, as necessary,
introduce remedial strategies in order to improve the quality of care and to conserve program funds or
personal expenditures. This activity is also intended to identify patterns of fraud, abuse, gross
overuse, or inappropriate of medically unnecessary care among physicians, pharmacists, and
recipients, or with respect to specific drugs or groups of drugs.
State Drug Use Review Board. Each State must provide for the establishment of a DUR board of
health practitioners (one-third to one-half physicians and at least one-third pharmacists) to help
implement the DUR program. Each State must require its DUR board to make annual reports to
DHHS on its activities and on cost savings resulting from the DUR program.
4-30
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-31
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
**Subject to the restrictions of the Oregon Health Plan.
PA = Prior Authorization, DME = Durable Medical Equipment, DMS = Durable Medical Supplies
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-32
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-33
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
**Subject to the restrictions of the Oregon Health Plan.
PA= Prior Authorization, DME = Durable Medical Equipment, DMS = Durable Medical Supplies
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-34
National Pharmaceutical Council Pharmaceutical Benefits 2007
Coverage of Injectables
Reimbursement for Non Self-Administered Medicines via
the Prescription Drug Program (PDP) or Physician Payment (PP)
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-35
National Pharmaceutical Council Pharmaceutical Benefits 2007
^ Early and Periodic Screening, Diagnostic and Treatment (EPSDT), Children Health Insurance Program (CHIP), Vaccines for
Children Program (VCP), or other.
LTC = Long Term Care
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-36
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-37
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make formulary/drug
decisions.
PA= Prior Authorization
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-38
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-39
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-40
National Pharmaceutical Council Pharmaceutical Benefits 2007
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-41
National Pharmaceutical Council Pharmaceutical Benefits 2007
Prior Authorization
Analgesics,
State Anabolic Steroids Antipyretics, NSAIDs Anorectics
Alabama Covered Covered, PA Required Covered, PA Required
Alaska Covered Covered Not Covered
Arizona* - - -
Arkansas Covered Covered, PA Required Not Covered
California Partial Coverage, PA Required Partial Coverage, PA Required Partial Coverage, PA Required
Colorado Covered, PA Required Partial Coverage, PA Required Not Covered
Connecticut Covered Covered Not Covered
Delaware Covered Partial Coverage, PA Required Partial Coverage, PA Required
District of Columbia Not Covered Covered Partial Coverage, PA Required
Florida Covered Covered Not Covered
Georgia Covered, PA Required Covered, PA Required Not Covered
Hawaii Covered, PA Required Covered Covered, PA Required
Idaho Not Covered Covered, PA Required Not Covered
Illinois Covered Covered Not Covered
Indiana** N/A N/A Not Covered
Iowa Covered Covered, PA Required Not Covered
Kansas Covered Partial Coverage Partial Coverage
Kentucky Covered, PA Required Covered, PA Required Covered, PA Required
Louisiana Covered Covered, PA Required Partial Coverage
Maine Covered, PA Required Covered, PA Required Covered, PA Required
Maryland*** Covered Covered Not Covered
Massachusetts Covered Partial Coverage, PA Required Not Covered
Michigan Not Covered Covered Not Covered
Minnesota Not Covered Covered Not Covered
Mississippi Covered Covered Not Covered
Missouri Partial Coverage, PA Required Covered Not Covered
Montana Covered Covered, PA Required Not Covered
Nebraska Not Covered Covered, PA Required Not Covered
Nevada Partial Coverage Covered Not Covered
New Hampshire Covered Covered, PA Required Covered, PA Required
New Jersey Covered Covered Covered
New Mexico Covered Covered Covered, PA Required
New York Covered Covered Not Covered
North Carolina Covered Covered, PA Required Not Covered
North Dakota Covered Covered Partial Coverage, PA Required
Ohio Partial Coverage Partial Coverage Not Covered
Oklahoma Not Covered Covered, PA Required Partial Coverage, PA Required
Oregon**** Covered, PA Required Covered Covered, PA Required
Pennsylvania Covered Covered Not Covered
Rhode Island Covered Covered Covered, PA Required
South Carolina Covered Covered Not Covered
South Dakota Covered Covered, PA Required Covered, PA Required
Tennessee Covered Covered, PA Required Not Covered
Texas Covered Covered Covered, PA Required
Utah Covered, PA Required Covered Not Covered
Vermont Covered Covered, PA Required Covered, PA Required
Virginia Covered Partial Coverage, PA Required Covered, PA Required
Washington Covered, PA Required Covered, PA Required Not Covered
West Virginia Covered Covered, PA Required Not Covered
Wisconsin Not Covered Partial Coverage, PA Required Covered
Wyoming Partial Coverage Covered, Some require PA Not Covered
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
** All coverage in accordance with OBRA'90 and OBRA'93.
***PA required for all drugs not on the preferred drug list.
****Subject to the restrictions of the Oregon Health Plan.
PA = Prior Authorization
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-42
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-43
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-44
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-45
National Pharmaceutical Council Pharmaceutical Benefits 2007
Prescribing/Dispensing Limits
Limits on
State Rx Limits on Number, Quantity, and Refills of Prescriptions
Alabama Yes 5 refills per Rx, 34 day supply per Rx, 4 brand limit per month
Alaska Yes 30 day supply per Rx, maximum number units for 50 classes and 40 narcotics
Arizona* - -
Arkansas Yes 31 day supply per Rx; 3 Rx per month (extension to 6); 5 refills per Rx within 6 months
California Yes 6 Rx per month, maximum 100 day supply for most medications, 3 claims per drug within 75 days
Colorado Yes 30 day quantity supply per Rx; 100 days maint. meds. Other limits may apply
Connecticut Yes 240 units or 30 day supply, 5 refills per RX except 12 month limit on oral contraceptives
Delaware Yes 34 day supply or 100 unit doses per Rx (whichever is greater) or by therapeutic category
District of Columbia Yes 34 day supply per Rx, 3 refills per Rx within 4 mos. Max/min quantities for certain meds
Florida Yes Vary according to the drug
Georgia Yes 34 day supply per Rx; Per Rx limit: $2999.99 (potential override)
Hawaii Yes 30 day supply or 100 unit doses per Rx, maximum quantities for some drugs
Idaho Yes 34 day supply per Rx (with exceptions); 3 cycles of birth control; limits on refills/early refills
Illinois Yes Medically appropriate monthly quantity, 3 brand scripts per month, daily dosage limits
Indiana No -
Iowa Yes Maximum 30 day supply except oral contraceptives (90 days); quantity limits on some drugs
Kansas Yes 31 day supply per Rx, 5 Rx per month, other limitations specific to certain medications
Kentucky Yes 32 day supply, max. 11 refills in 12 months; 93 days/100 units for maint. medication, 4 scripts/mo.
Louisiana Yes Greater of 30 day supply or 100 unit doses; 5 refills per Rx within 6 mos., max. 8 scripts/mo./recipient
Maine Yes 34 day supply (brand), 90 day supply (generic); Max. 11 refills per Rx, 4 brand scripts per month
Maryland Yes 34 day supply/Rx; 100 day supply for maint., max. 11 refills/ Rx, refills not to exceed 360 day supply
Massachusetts Yes 30 day supply, per month limits on some drugs, maximum 5 refills per prescription
Michigan Yes 34 day supply (100 days for maintenance), quantity limits for selected drugs (e.g., sedative hypnotics)
Minnesota Yes 34 day supply, quantity limits for selected drugs (triptans, antiemetics, sedatives pregabalin)
Mississippi Yes 31 day supply; 5 Rx per month (no more than 2 brand); 11 refills maximum
Missouri No -
Montana Yes 34 day supply
Nebraska No -
Nevada Yes 34 day supply per Rx; 100 day supply for maintenance medications. 5 refills within 6 months.
New Hampshire Yes 34 day supply, 90 day supply on maintenance medications, 5 refills within 6 months
New Jersey Yes 34 day supply or 100 unit doses per Rx, 5 refills within 6 months
New Mexico No -
New York Yes 5 refills per Rx; annual limit on number of Rx and OTC drugs avail. (potential override)
North Carolina Yes 34 day supply per Rx, with exceptions; 8 Rx per month with exceptions
North Dakota Yes 34 day supply per Rx
Ohio Yes 34 day supply; 102 day supply for maintenance medications; 5 refills per Rx
Oklahoma Yes 6 Rx (incl. 3 brands) per month (21+; under 21 unlimited), 34 day supply or 100 unit doses per Rx
Oregon Yes 34 day supply (100 days for mail order and maintenance drugs)
Pennsylvania Yes 34 day supply or 100 unit doses per Rx (whichever is greater); 5 refills within 6 mos., 6 Rx per month
Rhode Island Yes 30 day supply per Rx (non-maintenance); 5 refills per Rx
South Carolina Yes 34 day supply w/ unlimited Rx (children); quantity limits on some drugs, 4 Rx per month (adult)
South Dakota Yes Quantity limits that vary by drug
Tennessee Yes Varies by basis of eligibility
Texas Yes 3 Rx per month (unlimited Rx’s for nursing home recipients or those < 21), max 5 refills or 6 months
Utah Yes 31 day supply per Rx, max 5 refills, cumulative limit on specific drugs
Vermont Yes 34 days (102 days for maintenance medications), 5 refills per Rx
Virginia Yes 34 day supply per Rx
Washington Yes 34 day supply per Rx; 2 scripts per month; except antibiotics and schedule drugs, 4 brand cap
West Virginia Yes 34 day supply up to 11 refills, except antibiotics (14 days and 1 refill)
Wisconsin Yes 34 day supply per Rx with exceptions, 5 refills for Schedule III, IV, &V drugs, max.11 refills during
12-month period for non-schedule drugs
Wyoming Yes Quantity limits on some medications as deemed clinically appropriate.
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make formulary/drug
decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-46
National Pharmaceutical Council Pharmaceutical Benefits 2007
Medicaid Payment for Outpatient Prescription Drugs. Federal Medicaid regulations prescribe the
principles that apply to State Medicaid programs when they pay a pharmacy for outpatient drugs.
These regulations don’t just indicate the FFP cannot be based on amounts that exceed drug costs as
determined under the federal formula; they indicate the actual method for paying for prescription
drugs.
Medicaid Managed Care Organizations (MCOs). If the recipient is enrolled in a Medicaid managed
care organization, payment is made to the MCO in accordance with its contract with the State
Medicaid agency to the extent the contract covers outpatient prescribed drugs.
Medicaid Payment to Pharmacies. Each State’s Medicaid State Plan must comprehensively describe
its payment for prescription drugs. Its aggregate Medicaid expenditures for “multiple-source drugs”
must not exceed the Federal Upper Limits published by CMS (see Appendix D) and its payment level
for other drugs must not exceed, in the aggregate, the lower of (1) EAC plus a reasonable dispensing
fee, or (2) providers’ charges to the general public.
States are permitted to require certain recipients to share some of the costs of Medicaid by imposing
on them such payments as enrollment fees, premiums, deductibles, coinsurance, copayments, or
similar cost-sharing charges (42 CFR 447.50). For States that impose cost-sharing payments, the
regulations specify the standards and conditions under which States may impose cost-sharing, set
forth minimum amounts and the methods for determining maximum amounts, and describe
limitations on availability that relate to cost-sharing requirements.
With the passage of the Social Security Amendments of 1972, States were empowered to impose
“nominal” cost-sharing requirements on optional Medicaid services for cash assistance recipients, and
on any services for the medically needy. Section 131 of the Tax Equity and Fiscal Responsibility Act
(TEFRA) of 1982 introduced major changes to Medicaid cost-sharing requirements. Under this act,
States may impose a nominal deductible, coinsurance, copayment, or similar charge on both
categorically needy and medically needy persons for any service offered under the State Plan. Public
Law 97-248, TEFRA, has been in effect since October 1982; it prohibits imposition of cost-sharing
on the following:
! Services furnished to individuals under 18 years of age (or up to 21 at State option);
! Pregnancy-related services (or, at State option, any service provided to pregnant women);
! Services provided to certain institutionalized individuals, who are required to spend all of
their income for medical care except for a personal needs allowance;
! Emergency services;
! Family planning services and supplies;
! Services furnished to categorically needy HMO enrollees (or, at State option, services
provided to both categorically needy and medically needy HMO enrollees).
In addition, the law prohibits imposing more than one type of charge on any service.
While emergency services are excluded from cost sharing, States may apply for waivers of nominal
amounts for non-emergency services furnished in hospital emergency rooms. Such a waiver allows
States to impose a copayment amount up to twice the current maximum for such services. Approval
of a waiver request by CMS is based partly on the State’s assurance that recipients will have access to
alternative sources of care.
4-47
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-48
National Pharmaceutical Council Pharmaceutical Benefits 2007
Federal State-Specific
Upper Upper Limits
State Limits MAC Override Provisions
Alabama Yes Yes Brand medically necessary
Alaska Yes No Brand medically necessary and reason
Arizona* - - -
Arkansas Yes Yes Brand medically necessary plus MedWatch indicating why generics cannot be dispensed
California Yes Yes Medically necessary and product unavailable at MAC rate
Colorado Yes Yes Brand medically necessary
Connecticut Yes Yes No physician MAC override
Delaware Yes Yes MedWatch form for prior authorization
District of Columbia No No -
Florida Yes Yes Dispense as written plus multi-source brand drug form and prior authorization request
Georgia Yes Yes Brand medically necessary and Georgia Watch form
Hawaii Yes Yes PA plus brand medically necessary or do not substitute on script
Idaho Yes Yes Medically necessary with appropriate documentation
Illinois Yes Yes Prior authorization request by M.D. justifying need for brand
Indiana Yes Yes Brand medically necessary, prior authorization
Iowa Yes Yes Brand medically necessary and PA form
Kansas Yes Yes Prior authorization and MedWatch form
Kentucky Yes Yes Brand necessary, brand medically necessary, plus PA on some drugs
Louisiana Yes Yes Brand necessary, brand medically necessary
Maine Yes Yes Prior authorization
Maryland Yes Yes MedWatch form
Massachusetts Yes Yes Dispense as written and brand medically necessary, plus prior authorization
Michigan Yes Yes Brand medically necessary, plus prior authorization
Minnesota Yes Yes Dispense as written, brand medically necessary, must meet PA criteria
Mississippi Yes No Medically necessary, brand medically necessary, or PA for brand multi-source
Missouri Yes Yes Brand medically necessary, prior authorization and MedWatch form
Montana Yes No Brand necessary, brand required
Nebraska Yes Yes State-specific form
Nevada Yes Yes Dispense as written
New Hampshire Yes Yes Brand medically necessary
New Jersey Yes No Brand medically necessary
New Mexico Yes Yes Medically necessary, brand necessary, brand medically necessary
New York Yes No Prior authorization
North Carolina Yes Yes Brand medically necessary in writing on prescription
North Dakota Yes Yes Dispense as written
Ohio Yes Yes Prior authorization
Oklahoma Yes Yes Brand medically necessary plus prior authorization
Oregon Yes Yes Brand medically necessary plus prior authorization
Pennsylvania Yes Yes Brand medically necessary and prior authorization
Rhode Island No No Brand medically necessary with justification
South Carolina Yes Yes Brand medically necessary w/cert. by prescriber and prior authorization
South Dakota Yes No Prior authorization
Tennessee Yes Yes Dispense as written
Texas Yes Yes Brand necessary, brand medically necessary
Utah Yes Yes Dispense as written, prior approval, plus documentation
Vermont Yes Yes Dispense as written, medically necessary, brand necessary, or DAW 8 (generic not
available)
Virginia Yes Yes Brand necessary in physician’s own handwriting
Washington Yes Yes Brand medically necessary
West Virginia Yes Yes Brand medically necessary
Wisconsin No Yes Brand medically necessary plus prior authorization
Wyoming Yes Yes Brand medically necessary
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make formulary/drug decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-49
National Pharmaceutical Council Pharmaceutical Benefits 2007
Mandatory Substitution
*Within Federal and State guidelines, individual managed care and pharmacy benefit management organizations make
formulary/drug decisions.
Source: As reported by State drug program administrators in the 2007 NPC Survey.
4-50
National Pharmaceutical Council Pharmaceutical Benefits 2007
Sources: 12007 National Association of Boards of Pharmacy Law, Survey of Pharmacy Law; 2 As reported by State drug
program administrators in the 2007 NPC Survey.
4-51
National Pharmaceutical Council Pharmaceutical Benefits 2007
4-52
National Pharmaceutical Council Pharmaceutical Benefits 2007
Section 5:
State Pharmacy Program
Profiles
5-1
National Pharmaceutical Council Pharmaceutical Benefits 2007
5-2
National Pharmaceutical Council Pharmaceutical Benefits 2007
5-3
National Pharmaceutical Council Pharmaceutical Benefits 2007
5-4
National Pharmaceutical Council Pharmaceutical Benefits 2007
ALABAMA
Alabama-1
National Pharmaceutical Council Pharmaceutical Benefits 2007
C. ADMINISTRATION
Vaccines: Vaccines reimbursable as part of the
Alabama Medicaid Agency. Vaccines for Children Program.
Drug Benefit Product Coverage: Products covered: Formulary: Open formulary with preferred drug list.
disposable needles and syringe combinations used for Formulary managed through restrictions on use, prior
insulin; blood glucose test strips; and total parenteral authorization, preferred products, physician profiling,
nutrition. Products covered with restrictions: and academic dealing. Prior authorization required
prescribed insulin and syringe combinations used for for non-preferred drugs. Anti-psychotics and
insulin (on PDL and max units apply); and HIV/AIDs drugs are exempted from the prior
interdialytic parenteral nutrition (cert. of med. authorization requirements. (For additional
necessity on script). Products not covered: cosmetics information see: www.medicaid.alabama.gov)
(except through medical necessity); fertility drugs;
experimental drugs; urine ketone test strips; drugs for Prior Authorization: State currently has a formal
anorexia or weight gain/loss; hair growth products; prior authorization procedure. Prior authorization
and DESI drugs. decisions may be appealed by physician submitting
written notice along with medical documentation
Over-the-Counter Product Coverage: Products (i.e., peer reviewed literature and medical records) to
covered if prescribed by a physician: allergy, asthma the administrative services contractor for physician
and sinus products; analgesics; cough and cold review. The request is forwarded to the contractor’s
preparations (generics only); digestive products; Medical Director and the Agency’s Medical Director
topical products; prenatal vitamins; and hemorrhoidal for review.
products. Products not covered: feminine products;
smoking deterrent products. Prescribing or Dispensing Limitations
Therapeutic Category Coverage: Therapeutic Prescription Refill Limit: maximum of five refills for
categories covered: anablolic steroids; controlled substance, 11 for non-controlled.
anticoagulants; anticonvulsants; anti-psychotics;
chemotherapy agents; contraceptives; and thyroid Monthly Quantity Limit: 34-day supply.
agents. Partial coverage for: prescribed cold
medications. Prior authorization required for: Monthly Prescription Limit: four brand limit.
analgesics, antipyretics, and NSAIDs; anoretics;
antibiotics; antidepressants; antidiabetic agents;
Drug Utilization Review
antihistamines; antilipemic agents; anxiolytics;
sedatives, and hypnotics; cardiac drugs; ENT anti-
PRODUR system implemented in July 1996. State
inflammatory agents; estrogens; growth hormones;
currently has a DUR Board with a quarterly review.
hypotensive agents; misc. GI drugs;
sympathominetics (adrenergic); skeletal muscle
Pharmacy Payment and Patient Cost Sharing
relaxants; skin and mucous membrane agents; triptan
agents; respiratory agents; PPIs; platelet aggregation
Dispensing Fee: $5.40 (additional reimbursement for
inhibitors; Alzheimer’s Disease agents; ADHD
compounding).
agents; EENT anti-allergic agents; brand H2
antagonists; intranasal corticosteroids; narcotic
Ingredient Reimbursement Basis: AWP-10%, WAC
analgesics; specialized nutritional supplements;
+ 9.2%.
Retina A; Dipyridamole; Synagis; antihypertensive
agents; antiemetics; Xenical; and Xolair. Therapeutic
Prescription Charge Formula: Medicaid pays for
categories not covered: anoretics; prescribed smoking
prescribed legend and non-legend drugs authorized
deterrents; and OBRA 90 excludables.
under the program based upon and shall not exceed
the lowest of:
Coverage of Injectables: Injectable medicines
reimbursable through the Prescription Drug Program 1. The Federal Upper Limit or Maximum
when used in extended care facilities and home Allowable Cost (MAC) of the drug plus a
health care, and through physician payment when dispensing fee,
used in physicians’ offices.
Alabama-2
National Pharmaceutical Council Pharmaceutical Benefits 2007
Alabama-3
National Pharmaceutical Council Pharmaceutical Benefits 2007
Alison Wingate
Alabama Retail Association
Alabama-4
National Pharmaceutical Council Pharmaceutical Benefits 2007
Alabama-5
National Pharmaceutical Council Pharmaceutical Benefits 2007
Alabama-6
National Pharmaceutical Council Pharmaceutical Benefits 2007
ALASKA
Prescribed Drugs ! ! ! ! ! ! ! !
Inpatient Hospital Care ! ! ! ! ! ! ! !
Outpatient Hospital Care ! ! ! ! ! ! ! !
Laboratory & X-ray Service ! ! ! ! ! ! ! !
Nursing Facility Services ! ! ! ! ! ! ! !
Physician Services ! ! ! ! ! ! ! !
Dental Services ! ! ! ! ! ! ! !
*Total Other Expenditures/Recipients includes foster care children, 1115 demonstration participants, other recipients, and unknown.
Source: Alaska Medicaid Management Information System, FY 2005 and 2006.
Alaska-1
National Pharmaceutical Council Pharmaceutical Benefits 2007
Alaska-2
National Pharmaceutical Council Pharmaceutical Benefits 2007